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Biologically and therapeutically relevant compounds include drugs, bioactive 
compounds, food ingredients and additives, agrochemicals, metabolites, natural 
products, and toxic substances, which occupy special places in the chemical space 
with specific structural and physicochemical features for producing physiological or 
therapeutic functions on living organisms or for the metabolism by living systems. 
These compounds have common features for binding to biological macromolecules 
that can be characterized by their structural features (e.g. compounds of similar 
structures or pharmacophores bind to similar macromolecules), target properties (e.g. 
structural and physicochemical complementarity to the target sites, and targets of 
similar sequences may accommodate similar compounds) and activity profiles (e.g. 
quantitative structure-activity relationships). Characterization of biologically and 
therapeutically relevant compounds has been extensively used in diverse tasks of 
molecular and chemogenomic studies in applications such as drug discovery, 
chemical space navigation, structure-target relationship investigation as well as 
cross-pharmacology profiling. 
The aims of this thesis are (1) to extend the coverage of structure similarity based 
structural characterization from compounds of individual target classes to the more 
comprehensive sets of biologically and therapeutically relevant compounds, (2) to 
improve the target structure based characterization of compounds in such applications 
as molecular docking, and (3) to explore combined structure similarity based and 
target sequence similarity based characterization of compounds of the same target 
x 
 
families for facilitating such applications as ligand discovery, scaffold hopping and 
target hopping. 
Although similarity based methods have been extensively used for classifying and 
analyzing compounds, these often restricted to subsets of compounds individual 
targets. For facilitating the characterization of biologically and therapeutically 
relevant compounds and the orderly management of known compounds with respect 
to their functional categories, there is a need to systematically organize more 
comprehensive sets of compounds into chemical families based on structural 
similarity. In this thesis, a method for comprehensive characterization of compounds 
based on their structural similarity for definition, generation and maintenance of a 
comprehensive set of chemical families was developed. In order to better understand 
the intrinsic relationship and hierarchy among biologically and therapeutically 
relevant compounds, efforts were devoted to systematically define chemical families 
and select family members relevant to both structural and chemical studies and 
applications in pharmaceutical, biomedical, agricultural and industrial research and 
development. A seed-directed strategy for hierarchically organize these compounds 
was implemented. The results were presented in a function-based chemical families 
database CFam. 
Characterization of compounds from target perspectives, particularly from the 
perspective of their interaction against molecular targets enables the elucidation of the 
mechanism of action and guides the ligand discovery efforts. Such characterization 
can be achieved by using physical energy-based scoring functions. Current 
xi 
 
generalized scoring functions had unsatisfactory performances in predicting the 
binding affinity of compounds to their targets in the cases where co-crystal structures 
of the compounds with their targets are not available, and target-specific approaches 
were found to be a promising improvement. A method of tuning target-specific 
empirical scoring function was developed to predict binding affinity of compounds 
targeting specific receptor family. 
Combined characterization of bioactive compounds of specific target families from 
structural similarity and target sequence similarity perspectives facilitates the 
application of chemogenomic approaches for ligand discovery. A two-dimensional 
characterization method linking target sequence similarity with structural fingerprint 
based ligand similarity was used to derive a two-dimensional characterization based 
on target biding-site sequence similarity and ligand similarity. The method developed 
was tested on human G protein-coupled receptors (GPCR) and their ligands. The 
usefulness of this method was evaluated for characterization of comprehensive 
compound activity profiles and unexpected target associations, and focused on 
potential interest of applying chemogenomic approaches including scaffold hopping, 
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Characterization of biologically and therapeutically relevant 
compounds from structure and target perspectives 
 
 
Chapter 1 Introduction 
 
1.1 Biologically and therapeutically relevant compounds 
 
Biologically relevant compounds occupy special places in the chemical space with 
specific structural and physicochemical features for producing physiological or 
therapeutic functions on living organisms or for the metabolism by living systems. 
These compounds either naturally occur in living organisms or the environment, or are 
synthetic by chemical or biological methods. Therapeutically relevant compounds are 
biologically active and have common features for binding to biological 
macromolecules, thus exhibit the property to regulate the physical or mental states, and 
can be used in the treatment of physical or mental disorders or display such potential. 
Therapeutically relevant compounds discussed in this thesis include FDA approved 
drugs, drugs in clinical trial, investigative drugs and biologically active compounds 
display similar property, such as recreational drugs. These compounds are usually small 
molecules with molecular weight of several hundred Daltons, with several exceptions 
such as antibodies, which are proteins produced by living organisms to identify and 
neutralize foreign objects with molecular weights of hundreds of thousands Daltons. 
The rest of biologically relevant compounds can be classified roughly by their 
2 
 
functions or origins, such as human metabolite, natural products, food additives, 
agrochemical compounds and patented agents relevant to biological functions. As 
stated by the similar property principle [1], similar chemical structures between 
compounds result in similar physicochemical properties and biological activities. The 
functional category of a biologically relevant compound is largely determined by its 
structural features. Characterization of these compounds in unit of group of structural 
similarity can provide useful insight of the nature of their function. 
 
The various functions, i.e. physiological effects, of biologically and therapeutically 
relevant compounds are achieved by interaction with biological macromolecules, 
mostly protein enzymes, as their molecular targets. Protein targets have unique spatial 
arrangement of amino acid residues of different physiochemical properties at their 
binding site, thus only compounds with favorable structural features can bind to their 
respective targets. A compound can either act as the substrate or product of the 
enzymatic activity of a protein target, or inhibitor or activator with competitive or 
allosteric regulation. The interaction between the target binding site and the compound 
can be characterized by interaction energy, with affinity resulted from the lowering of 
energy through binding, i.e. the change of Gibbs free energy. The activities of 
biologically relevant compounds are dose dependent, and often a compound can bind to 
different targets, while a target can accommodate different compounds, as long as the 
lowering of energy through binding permits these interactions. Thus by 
characterization of activity profiles of compounds, information of quantitative 
structure-activity relationship (QSAR) can be obtained whose most useful application 
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is the prediction of binding affinities for unknown potential interaction. 
 
The scientific community has accumulated vast amount of data on biologically 
relevant compounds. The most comprehensive biological activity database PubChem 
[2] now contains more than 51 million unique compounds in over 1 million biological 
activity assays. With this large repository of activity data, collections of activities 
between biologically relevant compounds against targets become useful resources in 
characterization of compounds from the activity perspective. The similar property 
principle [1] holds because of the common structural features shared among similar 
compounds, and the structural features determine the ability of a compound for target 
binding. Also, as discussed above, biological targets determine the chemical features of 
their ligands by the arrangement of amino acid residues of different chemical features. 
Thus the extension of the similar property principle to biological targets leads to the 
implication that targets with similar structural features would have similar ligand sets.  
Now the entities in this collective analysis become compound groups and protein target 
groups formed by structural similarity, and the activity relationship between the 
compound and target groups. Chemogenomic approaches [3], whose ultimate goal is to 
identify all possible ligands for all targets, make use of such activity data for integrated 
analysis for ligand discovery and target deorphanization. 
 
 
1.2 Existing methods of characterization of biologically and 




1.2.1 Characterization of compound based on compound structures 
Compound can be characterized by their structure and physiochemical properties. For 
example, molecular weights, number of heavy atoms and number of rotatable bonds 
characterize the size of a compound; while solubility, polarity, lipophilicity, 
polarizability captures the overall physiochemical property. On the other hand, 
substructures and functional groups such as carboxyl, amine, long carbon chains or 
aromatic rings contribute to the interaction between hydrogen bond donors and 
acceptors, charged groups and hydrophobic groups. Also compounds can be 
characterized by their structural scaffold, e.g. salicylic acid and its analogs are often 
found to have anti-inflammatory activity, and compound with steroid scaffolds form 
several hormone groups such as glucocorticoids, mineralocorticoids, androgens, 
estrogens, and progestogens and vitamin D. In drug discovery, several rules of thumb 
are used to quickly determine the druglikeliness of a compound with combination of 
simple criteria, such as Lipinski's rule of five [4] and Oprea’s rule of three [5]. 
 
  Based on the above idea of description of compounds with structural features or 
physiochemical properties, characterization methods based on similarity groups were 
developed. By defining similarity with comprehensive set of features, clusters of 
compounds can be created and used as the basic unit of the study. Details of the 
definition and measurement of similarities can be found in Chapter 2 of methods. 
Similarity-based clustering and classification of compounds have been extensively 
used in diverse tasks ranging from the search of bioactive agents for drug discovery 
[6-9] to the molecular and chemogenomic studies in applications such as chemical 
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space navigation and analysis [10, 11], structure-target relationship investigation 
[12-17], cross-pharmacology profiling of intra-family and cross-family targets [18, 19], 
and receptor deorphanization [20]. In these studies, subsets of the chemical space 
covering compounds of interest were selected and hierarchically organized, and useful 
information can be derived from by comparison of similarity groups and their links to 
target activities. 
 
1.2.2 Characterization of compound based on target structures 
 
Characterization of target-binding compounds by target structures in terms of the 
interaction between the compounds and their targets provides useful insight on the 
mechanism of target binding process. Such insight facilitates ligand discovery and 
rational drug design since favorable structural features and their geometrical 
arrangement can be derived. Structural features of the compounds and the target 
binding sites determine the binding modes and affinities. Depending on the 
granularity required for such characterization, pharmacophore analysis and scoring 
function are commonly used approaches. 
 
A pharmacophore is an abstract concept deﬁned as “the ensemble of steric and 
electronic features that is necessary to ensure the optimal supramolecular interactions 
with a speciﬁc biological target structure and to trigger (or to block) its biological 
response” [21]. Ligand-based pharmacophore method uses conceptual models to 
describe the relationship between molecular structure and the target binding affinity. 
This concept works by classifying atoms based on their atom type and chemical 
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environment into predefined types such as hydrophobic, hydrogen bond acceptor or 
acceptor, positively or negatively charged groups, without quantifying the strength of 
interactions. Successively, a large number of compounds which are related to a 
specific interest, usually the binders of a protein target, are used to derive the common 
pharmacophore features from their structures to identify the pharmacophore 
requirements for activity. Such process is usually achieved by superimposing the set 
of ligand to obtain maximal overlap of their chemical features [22]. Usually a number 
of non-binders are used in conjunction with binders to help to verify the 
pharmacophore hypothesis. Various software packages exist for ligand-based 
pharmacophore modeling, such as Catalyst [23] and Phase [24]. Pharmacophore 
matching methods can then be employed in screening for active compounds for the 
target of interest. Pharmacophore analysis is widely used in characterization of 
compounds for virtual screening [25-27] and rational ligand design [28-30]. Examples 
include the design of SR13650, a antitumor compound with activity of nanomolar 
level based on pharmacophores of four metabolites of indole-3-carbinol [31], and the 
discovery of HIV-1 integrase inhibitor with activity of micromolar level by database 
screening with pharmacophore hypothesis consisting of nanomolar inhibitors [32]. 
Figure 1-1 illustrates a common feature pharmacophore model built from the training 
set of a study which aimed for the discovery of HIV-1 integrase inhibitor of the 






Figure 1-1 A common feature pharmacophore model built from the training set of a 
study which aimed for the discovery of HIV-1 integrase inhibitor of the quinolone 
3-carboxylic acid class [32]. The colors indicate different types of pharmacophore 
features: green for hydrogen bond acceptor, blue for negatively ionizable group and 
cyan for hydrophobic features. 
 
In addition to pharmacophore models constructed for binder compounds, 
pharmacophore analysis can also work on protein target binding sites to derive the 
pharmacophore requirement for active compounds. Target-based pharmacophore 
methods make use of 3D crystal structures of target binding sites or target-ligand 
complex structures to derive pharmacophore models. To generate such models, grids 
can be defined within the binding sites and various types of probe atoms are used to 
scan and score the grids. Finally only selected positions of the grids are retained to 
represent essential interactions required for ligands to exhibit activity against the 
targets. By comparison of pharmacophore models for two or more different targets, 
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common pharmacophore models can be derived to screen for multi-target inhibitors 
[33]. Various software packages exist for target-based pharmacophore model 
generation, such as LigandScout [34] and Pocket [35]. Target-based pharmacophore 
models have been used in ligand discovery for various targets, such as 
17b-Hydroxysteroid dehydrogenase type 1 [36] and bacterial DNA gyrase B [37]. 
 
Being able to characterize compounds with qualitative but not quantitative atom 
typing, pharmacophore analysis is of coarse grain as compared to scoring function. A 
scoring function usually employs empirical force field parameters to evaluate the 
interaction forces between the atoms pairs of the compound against the target binding 
site. Current scoring functions usually calculate hydrogen bonding interactions, van 
der Waals interactions, electrostatic interactions, hydrophobic effect and many other 
energy terms for each atom pairs from the ligand and the receptor in order to cover the 
complicated interaction between the ligand and the receptor at the binding site. Such 
scores are positively correlated with the free energy change upon binding (ΔG). 
 
One important application of scoring functions is to predict and rank binding poses 
generated in molecular docking. Usually the scoring function is calibrated with 
receptor-ligand complexes with known 3D crystal structures. The ligand in the 
structure of the complex is extracted and docked. The predicted binding poses are then 
compared to the native one by calculating the root mean square deviation (RMSD) of 
atom positions with the native binding pose, where the accuracy of the method is 
assessed. After the method is verified for being able to reproduce the binding pose in 
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the crystal structure, it can be used to dock other molecules to predict their poses when 
binding to receptors. Additionally, scoring functions can be used to predict the binding 
affinity of a molecule to a receptor based on docked binding poses or those from 
co-crystal structures. The binding affinity of a ligand to a receptor is actually the 
numerical answer to the question “how good does it bind”, so scoring functions possess 
innate relation with binding affinity. Often the change of Gibbs free energy (ΔG) of the 
system before and after ligand bounding is usually used to measure the binding affinity, 
which may also be expressed in dissociation constant Kd which has the following 
relation with ΔG: 
                    ΔG = −RTlnKd 
where T is absolute temperature and R is gas constant. Most scoring functions in 
docking produce scores which are positively correlated with ΔG, but in term of 
prediction such correlation is preferred to be linear[38]. The accuracy of binding 
affinity prediction is measured by comparing the predicted and experimental values, 
where the mean square error (mse) and correlation coefficient (R) is calculated. 
 
Scoring functions are also extensively used in the task of virtual screening, through 
which new drugs can be discovered for a specific target. In such situation, the interest is 
to rank order the compounds, to identify binders in a high throughput manner, so a fast 
docking method and an easy-to-calculate scoring function are always employed in such 
occasion. In such tasks, discrimination between binders and non-binders is the most 
important, rather than to predict the correct binding affinity and binding pose. To 
evaluate how good a scoring function is in virtual screening, speed and performance are 
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usually of concern. The receiver operating characteristic (ROC) curve[39] is usually 
reported for a screening run, which graphically plots the true positive rate vs. false 
positive rate for this binary classifying system as the threshold is varied, one point at 
one threshold value (usually by considering the top n percentage of the rank list as 
“hits”). Sometimes the area under curve (AUC) is also used. The ROC curve is 
connected with the nonparametric Wilcoxon statistic[40]. For a given threshold the 
following metrics help to evaluate the performance: true positive rate, true negative rate, 
false positive rate and false negative rate. 
 
Recent advances and technical aspects of scoring functions are discussed in detail 
in Chapter 4. 
 
1.2.3 Chemogenomic characterization of compounds by target sequence 
similarity 
 
As discussed previously, similarity based compound clustering characterization 
organizes the chemical space and guides virtual screening in various aspects. Similarly, 
biological targets, i.e. proteins, are also related in form of phylogeny. Molecular 
evolution of biological targets results in similarity between sets of targets known as 
homology groups. By analysis of sequences, motifs or 3D structures, similarity of 
targets can be defined and compared, and characterized by grouping them into 
subclasses with common features. Many classification systems were created, such as 
seed sequence alignment based protein family classification system Pfam [41, 42], 
conserved domain profiling of sequence segments database PROSITE [43], structure 
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classification methods with the aim of revealing evolutionary relationships for all 
proteins with known 3D structure SCOP [44] and CATH [44, 45], and analysis 
combining structures and functions InterPro [46]. 
 
Characterization of ligands by their structures jointly with their target similarity is a 
promising approach, as compound activities against targets associate individual ligand 
and target, providing extra information compared to characterization of compounds or 
targets alone. When such relationship is backed with ligand similarity and target 
similarity, a network of interaction can be constructed, resulting in a joint 
characterization of targets and ligands for chemogenomic analysis. By investigation the 
activity patterns of similarity groups of biologically active compounds, novel links to 
targets can be established, leading to potential cross-activity and providing insight for 
rational drug design [20]. On the other hand, relationship between targets can be 
established by ligand-set similarity [19] or ligand-framework similarity [20] by 
summarizing the similarities between ligand sets of different targets, providing a useful 
point of view of target similarity other than structure based phylogenetic study, where 
novel targets can be suggested for known compounds and deorphanization of targets 
can be facilitated.  
 
The characterization of compounds based on target sequence similarity provides a 
useful resource for ligand discovery and target deorphanization. Observations from 
successful experiences of navigation through the network lead to several strategies for 
chemogenomic analysis. Polypharmacology of a biologically active compound, also 
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termed a multi-targeting compound, is the case when a compound targets several 
different proteins [47-51], and in such situation, compounds of the same similarity 
group are promising candidates of similar pharmacological profile. Scaffold hopping 
refers to the discovery of novel molecular scaffold for the same target by modification 
of existing ligand scaffolds [52-55], whose direction of modification is usually guided 
by structural features from several similarity groups of the target of interest. Target 
hopping [56, 57] is different from scaffold hopping that the modification aims to 
decrease the activity of the current target of a compound and enhance activity to 
another, i.e. “hopping” from one target to another.  
 
The concept of chemogenomics arises when comprehensive analysis of “all possible 
drugs of all possible drug targets” [3] becomes necessary and important in modern drug 
discovery. Drug targets naturally form functional groups, such as GPCR, kinases, 
proteases and ligand-gated ion channels, etc.; while for drugs, chemoinformatic 
approaches can define their similarities based on substructures or physiochemical 
properties and further cluster the drugs into groups of similarity properties. By linking 
target families to drug families with binding affinity records, a network between drug 
targets and drugs can provide insight on discovery of new drugs or previously unknown 
interactions. Such idea extends to non-drug receptors as well. In the following sections, 
a series of strategies used in exploring the interaction between clustered ligands and 






The concept of polypharmacology is to design a single drug molecule which binds to a 
selection of targets simultaneously in order to achieve better efficacy via synergistic 
effects on regulation of multiple targets [58]. This is different from the dominant 
paradigm in drug discovery which aims to obtain a molecule with maximal efficacy 
and selectivity against a single target. 
 
According to retrospective analysis on binding affinity records, it is not rare that a 
molecule is potent against multiple proteins; actually it is quite common. By reviewing 
annotated public repositories of activity, it is reported that molecular scaﬀolds 
interacting with different number of targets are found in known active compounds; and 
the number of reported multi-targeting molecules are growing steadily [59]. Cases that 
the multiple targets are from the same protein family, as well as from different families, 
are observed. The basis of polypharmacology lies in the similarity of target binding 
sites, as well as in structure and property similarities of molecules [60]. It is speculated 
from the evolutionary point of view that early biological systems tend to evolve to 
exploit of as many chemicals available in environment as possible, and also to achieve 
systems that can adapt to changes of the constantly changing environmental conditions. 
 
Polypharmacological drugs may have improved efficacy over single-target drugs 
due to additive or synergistic effects [50]. Undesirable target-related adverse effect can 
also be reduced by decreasing the potency for target accountable for the adverse effect 
while synergistically interact with new targets [61]. In case of diseases with polygenic 
cause in the complex biological network, the redundancy of such network often renders 
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the effort to shut down a specific enzyme no effect due to activation of escape pathways, 
while targeting multiple enzymes redundant to each other can effectively regulate the 
network to the intended status. Furthermore, interaction and inhibition against multiple 
targets of similarity functions make the network less prone to resistance mutations. 
 
In the treatment of cancer, polypharmacology plays an important role in the 
therapeutic effect of various drugs, which usually target the ATP-binding site of 
kinases. Protein kinases form a large family with more than 500 members in human. 
Kinases are involved in cell growth, proliferation and survival, and a number of kinases 
are famous cancer targets and are under intensive investigation, such as PIK3K, EGFR 
and BRAF [62]. Kinases share conserved ATP-binding sites, making it difficult to 
selectively inhibit a certain kinase. However, this is not a problem that the effectiveness 
of cancer drugs is determined by their multi-targeting characteristic. For example, 
sunitinib was approved by the FDA for the treatment of renal cell carcinoma and 
imatinib-resistant gastrointestinal stromal tumor, and was found to target at least 79 
kinases [62]. As another example, sorafenib, a drug used to treat renal and liver cancers, 
was originally designed to target Raf kinase isoforms, but was later shown to inhibit 
other receptor tyrosine kinases such as PDGF and VEGF receptor tyrosine kinases [63]. 
Identification of polypharmacology helps to clarify the mechanism of therapeutic 
effects against cancers and improve the successful rates of rational drug design. 
 
Another area of disease treatment involves polypharmacology is the central nervous 
system (CNS) diseases. Drugs for treatment of mental disorders target primarily the 
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GPCRs. The endogenous ligands of GPCRs cover a wide range of chemical types such 
as amines, adenosines, peptides and lipids, so it is unlikely for individual drug to 
interact with many GPCRs from different endogenous ligand type groups, which is 
different from the case for kinases. However, polypharmacology for receptors of a 
certain endogenous ligand type does exist. One example is Clozapine, a drug designed 
to treat schizophrenia via binding to serotonin and dopamine receptors. Among these 
two types of amine receptors it interacts with, histamine receptor H1, the 5-HT2C 
receptor and alpha1-adrenoceptor were found to cause weight gain and associated 
metabolic adverse effects [64]. In such case, efforts on improving current drugs or 
discovery of new drugs against schizophrenia should be directed to achieve high 
selectivity towards the desired therapeutic targets. 
 
Polypharmacological effect can be detrimental if a drug or bioactive molecule under 
investigation interacts with undesirable targets (often called off-target or anti-target). 
This is especially harmful if a drug is released to the market without awareness of its 
adverse effect caused by off-target effect. For example, antihistamine drug Astemizole 
was marketed for allergic rhinitis and chronic idiopathic urticaria and it was withdrawn 
due to its potentially fatal side effects of arrhythmias because of hERG potassium 
channel blockade [65]. Ergoline-based dopamine receptor agonist Pergolide was used 
for the treatment of Parkinson's disease, which was withdrawn in year 2007 as it 
increased the risk of valvular heart disease [66] due to serotonin receptor agonism [67]. 
Such cases necessitate the early identification of polypharmacology during drug 




To detect detrimental polypharmacology in early stage of drug discovery, 
experimental screening as well as chemogenomic methods can be predictive. It is an 
established practice for research organizations to screen their candidates against panels 
of selected safety-relevant targets to detect severe adverse effect [51], which is named 
safety panel screening. Only frequently hit targets with clear relevance to adverse effect 
are screened, because the effort and cost are prohibitive to obtain the interaction profile 
of a potentially druggable candidate molecule against the human proteome. Also, 
targets sharing similar function or binding site structure naturally form target families 
or subfamilies, so representative targets can be picked instead of using the whole group 
to avoid redundancy [68]. On the other hand, computational methods help to predict 
off-target interactions based on prior knowledge and similarities among targets and 
their ligands. For example, an analysis on the binding cavity of GPCRs reveals the 
possibility to predict ligand-receptor interactions by receptor binding cavity features 
[69]. In another research, GPCRs were clustered by their sequence similarity as well as 
ligand set similarity with the aim of new ligand prediction and target deorphanization. 
 
Yet another aspect of polypharmacology is the potential opportunity of drug 
repurposing, often for drugs found to have detrimental off-target interactions. One 
example for drug repurposing based on off-target interaction is thalidomide, which was 
marketed as hypnotic since year 1957. Its efficacy in relief of pregnancy associated 
nausea making it frequently administrated to pregnant women in the first 4 years. 
However, it was revealed later that thalidomide was responsible for malformations in 
17 
 
fetal development. This teratogenic effect is possibly because of its induction of 
oxidative stress [70] or transcriptional interference [71]. Years after removal from the 
market, thalidomide was found to be active against tumor necrosis factor α (TNF-α) 
[72], which led to its repurposing into treatment of multiple myeloma. 
 
 
1.2.3.2 Scaffold hopping 
 
Scaffold hopping is a technique used to discover novel biologically active compounds 
based on a known active compound against the same target serving as a template. 
Starting from the template, structural variations are applied to the core structure, while 
maintaining feature essential to the desired activity, in hope of finding a new active 
compound with similar but new structure [52]. This concept was first introduced in 
1999 as a technique for discovery of novel calcium channel blocking agent [1], and 
application of scaffold hopping in drug discovery has been increasing ever since [73]. 
 
There are three major reasons for scaffold hopping being applied intensively [52]. 
First, physiochemical properties as well as pharmacokinetics of the template compound 
can be improved. For example, replacement of a lipophilic group into a polar one 
increases the solubility; in some other cases, modification of the central scaffold can 
increase the stability of an otherwise metabolically labile compound. Second, binding 
affinity can be improved by replacement or modification of functional groups or even 
the core scaffold. In this way potent compound with low binding affinity can be 
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optimized. Last, application of scaffold hopping on patented compounds can lead to the 
discovery of patentable novel structures. 
 
A scaffold representation scheme widely used in the area of drug discovery is the 
Murcko framework [74] proposed by Bemis and Murcko in 1996. This method focuses 
on the ring system of a compound. It dissects molecular structures into ring systems, 
linkers and side chain atoms. The ring systems are defined as single and fused rings, 
and the linkers are chains of atoms connecting the ring systems, and side chains are the 
rest atoms. The concept of scaffold in scaffold hopping is closely related to the above 
definition that it considers two scaffolds different as long as they are to be synthesized 
through different routines[52]; and this will usually results in different Murcko scaffold 
frameworks. As stated by the similar property principle[1], similar chemical structures 
between compounds results in similar physicochemical properties and biological 
activities. Thus the structural variation in scaffold hopping should maintain some key 
features to keep the desired activity while achieve a novel structure. 
 
Scaffold hopping can be classified based on the degree of changes made to the 
template compound, and a four degree classification system was introduced in a 
review[55]: 1° hop, replacing or swapping of carbon and heteroatom in ring systems; 2° 
hop, ring opening and closures; 3° hop, replacement of peptide backbones into 
non-peptide structures and 4° hop, completely new structure with interaction features 




An example demonstrating the impact of 1° scaffold hopping is the discovery of 
DuP697 analogous diarylheterocyclic family of selective COX-2 inhibitors. DuP697 
(Figure 1-2 1a) was the first discovered selective COX-2 inhibitor[75], and served as 
building blocks for subsequence selective COX-2 inhibitor discovery. Rofecoxib and 
celecoxib (Figure 1-2 1b and 1c) differ from DuP697 and each other in the backbone 
heterocyclic ring, while all three selective COX-2 inhibitors share comparable 
activity[76]. Heterocyclic replacement has improved the pharmacology that although 
Dup697 and rofecoxib either failed to reach the market or withdrawn, celecoxib is still 
in the market for treatment of osteoarthritis, rheumatoid arthritis, and acute pain, etc. 
[76]. 
 
2° scaffold hopping is illustrated with a ring closure case, where the position of 
closure is hinted by intramolecular hydrogen bond. Hydrogen bond observed between 
o-alkoxy group and biaryl NH (Figure 1-2 2a) lead to the synthesis of a series of indole 
compounds for prostaglandin EP1 receptor inhibitor discovery [77]. One compound 
(Figure 1-2 2b) exhibited nanomolar level activity, which is partly due to the ring 
closure fixed the molecule at the active conformation. 
 
Peptidomimetic replacement is classified as 3° scaffold hopping. The second 
mitochondria-derived activator of caspases (Smac) interacts with X-linked inhibitor of 
apoptosis (XIAP) with four amino acid residues of its N-terminal sequences, inducing 
cell apoptosis. Starting from a tetrapeptide AVP-2,2-diphenylamine (Figure 1-2 3a) as 
potent template[78], a bicyclic motif was identified as replacement of one of the amino 
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acids through literature search[79]. The resulting azabicycloocatane compound (Figure 
1-2 3b) demonstrated binding affinity of nanomolar level against XIAP [78]. This 
peptidomimetic replacement strategy increases the drug-likeness of a compound 
compared to peptides, also the pharmacokinetic properties and bioavailability. 
 
As for 4° scaffold hopping, the topology or shape-based searching strategy usually 
results in completely new structure with interaction features retained. An example can 
be found in the pursue of antibiotics that interrupts bacterial cell wall biosynthesis by 
targeting the ZipA-FtsZ protein–protein interaction[80]. One of the initial hits from 
high-throughput screening (Figure 1-2 4a) with low binding affinity was found to have 
toxicity concern and intellectual property (IP) issue, so a shape-based Rapid Overlay of 
Chemical Structures (ROCS) search was carried out. The hit of ROCS had no toxicity 
or IP issue while retaining interaction features as compared with its template, and could 





Figure 1-2 Examples for scaffold hopping 1°, 2°, 3° and 4°. Adapted from [55]. 
1a: cox-2 inhibitors DuP697; 1b: celecoxib; 1c: refocoxib; 
2a: biaryl amine series; 2b: indole series; 
3a: modified Smac tetrapeptide; 3b: an azabicyclooctane analog; 






As illustrated by the above examples of scaffold hopping, apart from literature search 
and the knowledge of experienced researchers, computational approaches may aid in 
the identification of suitable novel scaffolds. Four major approaches are widely used, 
namely shape matching, pharmacophore searching, fragment replacement and 
similarity searching. Shape matching is similar to pharmacophore searching that both 
methods requires the knowledge of the spatial arrangement of functional groups in a 
compound as well as 3D conformations. The difference is that, pharmacophore 
searching is based on the interaction features at the compound side such as hydrogen 
bond donor or hydrophobic groups, while shape searching does not emphasize the 
relative importance of functional groups. Fragment replacement can discover novel 
scaffolds for either 2D or 3D structures, but the level of novelty as well as the 
interaction features retained may vary depending on different criteria setting for the 
query. The last method, similarity searching, is an idea that abstracts the features of a 
compound into set of binary bits or descriptor values and retrieves hits based on the 
similarity of these bits or values. Software programs used in scaffold hopping may 
provide one of the above four approaches, or a combination of them. Commonly used 
software for scaffold hopping includes ROCS for shape matching[81], Catalyst for 
pharmacophore searching[23], CAVEAT for fragment replacement[82] and different 






1.2.3.3 Target Hopping 
 
Target hopping is an approach to discovery novel interaction for one target starting 
from inhibitors of another target with similar interaction features. As can be explained 
by the principle of similarity, it is usually observed that a set of similar compounds 
bind to a set of targets with similarity interaction features, or more stringent, 
similarity binding sites. In such case, one can choose among the set of similar 
compounds and apply derivatization to enhance of obtain selectivity against one of the 
targets. 
 
The idea can be exemplified by the design of selective Factor VIIa tissue factor 
complex (FVIIa/TF) inhibitor from dual inhibitors for thrombin and FVIIa/TF [56]. 
An initial hit from screening (Figure 1-3 a) was identified as dual inhibitor of FVIIa/TF, 
with activity against FVIIa/TF and thrombin are 2400 nM and 88 nM, measured in 
IC50, respectively. In order to discover selective FVIIa/TF inhibitor from this 
compound as template, the interactions of this compound and the binding pockets of 
FVIIa/TF and thrombin were analyzed and a derivative, as shown in Figure 1-3 b, was 
designed and synthesized. Binding assay confirmed increased selectivity over thrombin 
as the binding affinities for FVIIa/TF and thrombin have changed to 25 nM and 150 nM, 
respectively. This is now a potent dual inhibitor for both of the targets. Based on this 
intermediate result, a second round derivatization was applied to further increase the 
selectivity. In the final results, one of the compounds (Figure 1-3 c) had binding 
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affinities against FVIIa/TF and thrombin of 30 nM and 25300 nM, which is a highly 
selective. The modified structure moieties were colored in red in Figure 1-3. 
 
Another recent example is the discovery of selective EphA2 receptor inhibitor 
lithocholic acid (LCA) derivatives using LCA, which is an endogenous ligand for the 
nuclear receptor FXR and the G-protein-coupled receptor TGR5 but also an antagonist 
of the EphA2 receptor, as template[57]. The derivatization procedures were guided by 
the difference of receptor-ligand interaction features, and a stilbene carboxylic acid 
compound was identified as a highly selective antagonist of EphA2. 
 
The target hopping approach emphasizes the comparative analysis of interaction 




Figure 1-3 Selected FVIIa/TF and thrombin dual inhibitors illustrating target hopping 





1.3 The need for more comprehensive characterization 
 
As mentioned in previous sections, structure-based characterization of compounds 
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leads to the development of similarity-based methods for virtual screening and ligand 
discovery. However, previous efforts often focus on compounds of specific target 
activities [6, 8, 9] or specific combinatorial libraries in search for novel ligand of 
specific targets; or aims to map and navigate the chemical space by hierarchically 
organize a subset of the chemical space without discrimination of their functional 
categories [7, 10, 11]. For facilitating the characterization of biologically and 
therapeutically relevant compounds and the orderly management of known compounds 
with respect to their functional categories and the study of new compounds, it would 
be advantageous to organize the known compounds into chemical families based on 
structural similarity [83, 84]. This requires a method and resource for defining, 
generating and maintaining a comprehensive set of chemical families, and such a 
resource is not yet publically available. 
 
Current characterization of compounds with respect to their targets in terms of 
activities with scoring functions is yet to be a perfect method. The performances of 
scoring functions in prediction binding affinity for docked ligands are known to be 
unsatisfactory. A comparative assessment of 16 popular scoring functions in year 2009 
reported that the correlation coefficient R between predicted and experimental binding 
constants ranged between 0.545 and 0.644 [38]. Some other studies also discussed the 
poor performance of scoring function in predicting binding affinity [85, 86]. On the 
other hand, target specific approaches used in characterization of compounds with 
respect to target activities have gained increasing attention. A target specific scoring 
function is trained with data only within the target or target group of interest, and then 
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used to prediction the binding pose, binding affinity of new compounds, or to screen a 
library for potential binders. Such narrowing down of the training dataset selection 
allows better performance on the target group, compared with the generalized scoring 
functions, as exemplified by several successful attempts such as the AutoShim [87], 
and the POEM [88] methods. However, these methods either make use of in house 
activity data with recursive model construction, or derive their prediction model from 
limited number of co-crystal structures. Thus there is a need to develop a method 
which is able to predict large number of ligands without co-crystal structures available 
in a target specific manner with satisfactory performance, in order to better 
characterize compounds from the target interaction perspective. 
 
As discussed above, there is a need for characterization of compounds in terms of 
their individual target binding activity, and this is also the true for characterization of 
compounds from their target sequence similarity. Current methods of characterization 
of ligand sets and targets organize ligands by structural similarity or molecular 
scaffolds, and relationship between targets established by ligand-set similarity [19]. 
Target sequence similarity-based characterization of compounds enables 
chemogenomic analysis [20, 89-91] on both compounds and their targets. However, 
current methods sometimes inadequately reveal target associations of compounds, 
usually because that the analysis was based on ligand-set similarity and target 
similarity respectively, not making full use of their interaction information. 
Interaction between a certain target-ligand pair may seem isolated from another, but 
when inspected jointly with target and compound similarity groups, the previously 
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isolated interaction pairs may be found to relate to each other due to the similarity 
between the ligands and the targets, respectively. There is a need to comprehensively 
capture both primary and secondary target associations as well as characterize 
compounds by their activity profiles to facilitate the application of chemogenomic 
approaches for ligand discovery, such as scaffold hopping [52-55], target hopping [56, 
57], and polypharmacology [47-51]. 
 
1.4 Objectives and outline of this thesis 
 
The objectives of this thesis focus on extension and improvement of the methods 
which characterize biologically and therapeutically relevant compounds from various 
aspects. Ligand-based virtual screening methods require similarity information of 
ligands, so there is a need for comprehensive organization of functional compounds 
into similarity families, and such resource is not publicly available yet. On the other 
hand, compounds can also be characterized by interactions with their targets, where 
scoring functions with improved predictive power for binding affinity are required. In 
addition, the combination of compound similarity and target similarity in ligand 
discovery has led to successful applications of chemogenomic strategies such as 
scaffold hopping, target hopping and polypharmacology, thus a joint characterization 
method combining compound and target similarity information needs to be developed 
and evaluated for the revelation and summarization of the abovementioned 
chemogenomic strategies as well as prediction for novel activity based on those 
strategies. Achieving these objectives would help in the characterization of 
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biologically and therapeutically relevant compounds for virtual screening. 
 
In this thesis, a method for comprehensive characterization of compounds was 
developed. In order to better understand the intrinsic relationship among biologically 
and therapeutically relevant compounds, efforts were devoted to systematically define 
chemical families and select family members by both structural and functional 
characteristics, to facilitate research and development in pharmaceutical, biomedical, 
agricultural and industrial applications. A seed-directed method to hierarchically 
organize these compounds was implemented, resulting in a database of 
similarity-based functional chemical families -- the Chemical Family database CFam. 
Such effort aims to extend the coverage of structural similarity based characterization 
from compounds of individual target classes to a more comprehensive set of 
biologically and therapeutically relevant compounds. The outcome as a database 
provided a useful resource in virtual screening by characterization of compounds by 
structural similarity, as well as a novel scalable algorithm to organize large number of 
compounds by their functions. 
 
In succession to characterization of compounds from the structural similarity 
perspective, it is desirable to characterize compounds from their target structures in 
terms of binding activities. As discussed previously, more accurate characterization 
can be achieved in a target-specific manner. A method of tuning target-specific 
empirical scoring function was developed to predict binding affinity of compounds 
targeting specific receptor family for ligands whose co-crystal structures with the 
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receptor are not available, to provide a useful method for characterization therapeutic 
compounds in a high throughput context. With this method, target-specific scoring 
functions were tuned for several target systems, and the predictive power of these 
models were compared with previous publications on target-specific scoring functions 
as well as with scoring functions of popular molecular docking programs. 
 
With characterization of compounds from structural and target-binding aspects, a 
more comprehensive characterization jointly considering target sequence similarity 
and compound structure similarity was developed to further characterize biologically 
and therapeutically relevant compounds. A two-dimensional characterization method 
linking target sequence similarity [20, 69, 92] with structural fingerprint [93, 94] based 
ligand similarity was used to derive a two-dimensional target-site sequence similarity 
and ligand-similarity characterization. The method developed was applied on human 
G protein-coupled receptors (GPCR) and their ligands. The usefulness of this method 
was evaluated for characterization of comprehensive compound activity profiles and 
unexpected target associations, and focused on potential interest of applying 
chemogenomic approaches including scaffold hopping, target hopping and 
polypharmacology for ligand discovery and target deorphanization. The usefulness of 
this method was validated by the experimental confirmation of novel activities 















Chapter 2 Methods used in this thesis 
 
2.1 Defining similarity for molecules 
 
Definition of similarity for molecules is the foundation of many applications of 
chemoinformatics in computational biology such as virtual screening and bioactive 
chemical space navigation. The similar property principle assumes that molecules with 
similar structures exhibit similar properties, and furthermore, bioactivity towards a 
certain target [95, 96]. This is the rational basis for the practice in the area of drug 
discovery, e.g. high throughput screening and lead optimization[97]. Given an active 
molecule as a reference, the molecules in a large database can be compared to the 
reference molecule in terms of structural similarity, and those with high similarity to the 
reference are more likely to be active. 
 
2.1.1 Molecular descriptors 
 
Molecular descriptors are mathematical values that describe the structure or shape of 
molecules [98] and used to represent or predict various properties of a molecule. The 
widely accepted definition was coined by Todeschini and Consonni in year 2000 as “the 
ﬁnal result of a logic and mathematical procedure which transforms chemical 
information encoded within a symbolic representation of a molecule into a useful 
number or the result of some standardized experiment”[99]. Starting from molecular 
structure, molecular descriptors are calculated through application of different theories, 
such as graph theory, quantumchemistry, physical chemistry, etc. to represent 
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properties of various aspects of a molecule. A set of carefully selected molecular 
descriptors can uniquely represent a molecule in the chemical space in most cases. To 
date, thousands of molecular descriptors have been defined, and they can be roughly 
classified into six classes by their nature, namely constitutional descriptors, electronic 
descriptors, physicochemistry descriptors, topological indices, geometrical molecular 
descriptors, and quantum chemical descriptors[100]. 
 
There are a number of software packages and libraries available to calculate 
molecular descriptors, such as VCCLAB[101], DRAGON[102], Molconn-Z[103], 
JOELib[104], MODEL[100], PaDEL[105], CDK[106] and RDKit[105]. 
 
Since molecular descriptors capture the physiochemical aspect of molecular 
properties, it is widely used to predict binding affinities or physiochemical properties in 
chemical or biochemical scenarios such as QSAR modeling. As it helps to define 
distance and similarity, molecular descriptors are also used in virtual screening based 
on machine learning methods as well as partitioning of chemical space of interest. 
 
2.1.1.1 The need for feature selection 
 
Due to the individual consideration of the problem being modeled and different 
predictive ability and interpretability of different molecular descriptors, the set of 
molecular descriptors to be used should be carefully chosen. On the other hand, large 
number of molecular descriptors can bring in too many dimensions to the model and 
result in drastic increase in computational cost. Indiscriminative use of molecular 
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descriptors may also bring in excessive noise since chemical information useful to a 
specific problem can get overwhelmed by redundant or non-relevant properties. Thus it 
is often necessary to perform feature selection on the available molecular descriptors. 
The process of feature selection selects a subset of features (here the features are 
molecular descriptors) with strong statistical significance with various statistical 
methods, resulting in a model with more interpretability, better performance and less 
computation cost. 
 
In this study a set of 98 molecular descriptors were used, which were previously 
chosen and used in a series of virtual screening work [107-110] and has demonstrated 










Simple molecular properties  18 Number of C, N, O, P, S, Number of total atoms, Number of rings, Number of bonds, 
Number of non-H bonds, Molecular weight, Number of rotatable bonds, number of H-bond 
donors, number of H-bond acceptors, Number of 5-member aromatic rings, Number of 
6-member aromatic rings, Number of N heterocyclic rings, Number of O heterocyclic rings, 
Number of S heterocyclic rings.  
Chemical properties 3 Sanderson electronegativity, Molecular polarizability, Alogp 
Molecular Connectivity and 
shape 
35 Schultz molecular topological index, Gutman molecular topological index, Wiener index, 
Harary index, Gravitational topological index, Molecular path count of length 1-6, Total path 
count, Balaban Index J, 0-2th valence connectivity index, 0-2th order delta chi index, 
Pogliani index, 0-2th Solvation connectivity index, 1-3th order Kier shape index, 1-3th order 
Kappa alpha shape index, Kier Molecular Flexibility Index, Topological radius, 
Graph-theoretical shape coefficient, Eccentricity, Centralization, Logp from connectivity. 
Electro-topological state  42 Sum of Estate of atom type sCH3, dCH2, ssCH2, dsCH, aaCH, sssCH, dssC, aasC, aaaC, 
sssC, sNH3, sNH2, ssNH2, dNH, ssNH, aaNH, dsN, aaN, sssN, ddsN, aOH, sOH, ssO, sSH; 
Sum of Estate of all heavy atoms, all C atoms, all hetero atoms, Sum of Estate of H-bond 
acceptors, Sum of H Estate of atom type HsOH, HdNH, HsSH, HsNH2, HssNH, HaaNH, 






2.1.2 Substructure fingerprint 
 
Substructure fingerprints is another way to describe a molecule and enable similarity 
searching. The main idea of substructure fingerprint is to encode the presence or 
absence of certain substructures in a molecule with bits with values 1 or 0, thus a 
substructure fingerprint of a molecule is actually a bit-string which enables simple and 
fast comparison between molecular structures. A carefully selected set of substructures 
efficiently capture the similarity and diversity of a group of molecules, thus facilitates 
screening and clustering. 
 
The first defined substructure fingerprint appeared in year 1985 as atom pairs used 
for similarity search and activity prediction [111]. Through years of application in the 
field of virtual screening, the substructure fingerprint commonly used today contains 
hundreds to thousands of bits, such as the MDL keys (MACSS structure-based) [112], 
the dictionary-based PubChem substructure fingerprint [2] and the Klekota-Roth 
fingerprint[113]. These fingerprint sets covers a wide range of substructures which are 
of interest to bioactivity, such as aromatic and non-aromatic rings of different sizes, 
rings with heteroatoms and substructures participating in hydrogen bonds. A lot of 
open-source software packages or libraries can be used to generate substructure 
fingerprints, such as PaDEL[105], Open Babel[114], CDK[106] and RDKit[115]. In 
this thesis the PubChem fingerprint is used. Selected bits from the PubChem 




Table 2-2 Selected bits from PubChem fingerprints from each section. Patterns are defined both descriptively and in SMARTS patterns. 
 
Section Bit Position Bit Substructure 
Section 1: Hierarchic Element 
Counts 
0 >= 4 H 
1 >= 8 H 
2 >= 16 H 
Section 2: Rings in a canonic 
Extended Smallest Set of Smallest  
Rings (ESSSR) ring set 
115 >= 1 any ring size 3 
116 >= 1 saturated or aromatic carbon-only ring size 3 
117 >= 1 saturated or aromatic nitrogen-containing ring size 3 





























2.1.3 Measurement of similarity – Euclidean distance 
 
Since molecular descriptors are real numbers, a set of molecular descriptor values of 
a molecule can be considered a point in high-dimensional Euclidean space, and the 
commonly used distance metrics between two molecules represented by their 
molecular descriptors is the Euclidean distance: 




where x, y are molecules with n molecular descriptors each, D(x, y) is the Euclidean 
distance between them, and xi, yi are values of molecular descriptors at position i. The 
Euclidean distance meets the triangle inequality. 
 
2.1.3.1 Scaling of molecular descriptors 
 
Before using molecular descriptors in any modeling process, the values are usually 
scaled to make sure each descriptor contribute equally[116]. For example in the 
calculation of the aforementioned Euclidean distance, if a certain descriptor has a value 
range at an order of magnitude much larger than the other descriptors, it will 
dominantly determine the distance between the two molecule, rendering the 
contribution of other descriptors – which may be of great predictive power – negligible. 









where dij’, dij are the scaled and original value of descriptor j of molecule i, dj,min and 
dj,max are the minimum and maximum values of descriptor j for all molecules, 
respectively. The scaled descriptor values fall between 0 and 1. 
 
2.1.4 Measurement of similarity – Tanimoto distance 
 
Since substructure fingerprints are set of 0 or 1 bits, the convenient way to measure 
similarity between two set of fingerprints is to consider the number of bits which are 1 
in both sets. Take the total number of bits into consideration, the Tanimoto 
coefficient[117], also called the Tanimoto similarity, which is actually the bit-string 
version of the Jaccard index[118], is used in this thesis for the measurement of 
similarity between fingerprints of two molecules: 
T𝑠(𝑥𝑖, 𝑦𝑖) =
∑ 𝑥𝑖 & 𝑦𝑖𝑖
∑ 𝑥𝑖  | 𝑦𝑖𝑖
 
where x, y are fingerprints for two molecules, and xi, yi are the ith bits in each 
fingerprint, while “&” and “|” denotes bitwise “and” and bitwise “or”, respectively. 
This value is the number of common substructure features divided by the total number 
of unique substructures existing in both molecules, and has the range (0, 1]. After this 
similarity, a distance called the Jaccard distance is defined as follows: 
J𝑑(𝑥𝑖, 𝑦𝑖) = 1 − T𝑠(𝑥𝑖, 𝑦𝑖) 





It is reported that in selected datasets for study, a group of molecules with Tanimoto 
similarity larger than 0.85 to an active molecule against a certain target, are active for 
more than 85% of themselves[120]. This is termed the “neighborhood behavior” and 
has set a putative standard in virtual screening, which is an activity cut-off of similarity 
from the active molecule. The study was done with 166-bit MACCS keys, so when 
using the 881-bit PubChem fingerprint which captures more substructure 
characteristics this cut-off becomes more stringent. 
 
2.1.5 Molecular scaffolds and scaffold clustering 
 
2.1.5.1 Definition of molecular scaffolds 
 
The structure of a molecule can be viewed as a collection of components of three 
different types: ring systems, linker atoms and side chain atoms[74]. The ring systems 
are defined as individual cycles and cycles sharing edges, representing the rigid cores 
of a molecule. Linker atoms are atoms on a path connecting two ring systems. Side 
chain atoms are those neither in a ring system nor a linker atom. The scaffold of a 
molecule (also called framework) refers to all connected ring systems and linkers, as 
visualized in Figure 2-1. This scaffold definition emphasized the rigid cores – ring 
systems of a molecule, with linkers and side chains derived from the definition of ring 
systems. Generation of molecular scaffold from structure is also known as Murcko 






Figure 2-1 Definition of ring systems, linker atoms and side chain atoms using 
nucleoside analog reverse transcriptase inhibitor Abacavir as example. 
 
 
2.1.5.2 Comparing molecular scaffolds quantitatively 
 
Since molecular scaffolds are graphic representation of a molecule, it is not quantitative 
in nature. Efforts have been made to develop methods to compare molecules by their 
scaffolds quantitatively. One such method is SIMCOMP[121], which is based on 
maximal common subgraph (MCS) detection. The Jaccard coefficient between two 
molecules is defined on their molecular graphs as: 
Jc(𝐺1, 𝐺2) =
|MCS(𝐺1, 𝐺2)|
|𝐺1| + |𝐺2| − |MCS(𝐺1, 𝐺2)|
 
where |𝐺| is the cardinality of graph G. MCS detection can be time consuming, thus in 
order to speed up the calculation optimization and approximation were used to obtain 
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the Jaccard coefficient. This way a value between 0 and 1 is defined as similarity of two 
molecules base on their scaffolds, enabling the hierarchical clustering method on 
molecular scaffolds.  
 
2.1.5.3 Scaffold clustering methods 
 
Unlike the attempt of quantitatively defining similarity between molecular scaffolds, 
scaffold clustering methods derive the hierarchical relationship from molecular 
scaffolds directly. There are two types of approach to construct scaffold hierarchy: 
top-down and bottom-up. The top-down approach deconstructs one ring system at a 
time and group molecules at different level by matching the remaining structures at 
each step. The bottom-up approach first breaks apart scaffolds into individual minimal 
ring systems and then combines them exhaustively to generate all possible 
combinations and group molecules at different level of combination. These approaches 
can be substantially faster than quantitative comparison of scaffold pairs because no 
MCS detection is involved. 
 
Several software packages are available for scaffold clustering. One example is the 
popular Scaffold hunter[122] which uses the top-down approach. Starting from the 
scaffold of a molecule, by deconstruction of one ring at a time successively, virtual 
scaffolds of different deconstruction level can be obtained. The molecules are then 
grouped at different level of virtual scaffolds to form scaffold hierarchy. In this process, 
the pre-defined set of rules for choosing the next ring to dismantle is of crucial 
importance to the scaffold hierarchy generated and calculation speed. The set of rules 
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prefers small ring systems over large ones, and connected ring systems over fused ring 
systems. Such rules capture and preserve the core structure of a molecule and result in 
reasonable scaffold trees that are easy to interpret. 
 
Another example is the HierS method featuring a bottom-up approach[123], where 
all individual ring systems are considered the building blocks of molecules and defined 
as “basis scaffolds”. Starting from the scaffold of a molecule, every combination of 
basis scaffolds present in the molecule are generated and termed “intermediate 
scaffolds”. Given a set of molecule, all intermediate scaffolds from all molecules can be 
obtained. Within this list of all intermediate scaffolds, starting from the smallest ones, 
all intermediate scaffolds were used in superstructure search against all others. The 
scaffold hierarchy can then be determined according to membership between all 
intermediate scaffolds. Finally molecules are assigned to different levels of the 
hierarchy if a molecule is a superstructure of the intermediate scaffold at a certain level. 
 
There are still other software packages or implementations of scaffold clustering 
such as the proprietary software Molinspiration Clusterer [124]. Another in house 
implementation of scaffold tree employed a simplification scheme on fused ring 
systems using Molinspiration toolkit [125]. 
 
Scaffold clustering was applied intensively in chemical space navigation [122], as 
well as optimization of activity and structural diversity of high through-put screening 
[123]. This method is intuitive that the scaffolds are actually part of the molecular 
structure with shapes easy to recognize, making similarity search and analysis easy 
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when retrieval or enrichment of structures containing a certain core is desired, 
compared to substructure fingerprint approach which models molecules in an abstract 
and structural feature oriented way. 
 
2.2 Defining similarity for protein sequences 
 
2.2.1 Protein similarity based on protein sequence alignment 
 
2.2.1.1 Sequence alignment 
 
Sequence alignment is a method to arrange biological sequences, usually protein, DNA 
or RNA, to identify regions of similarity and guide the inference of functional, 
structural and phylogenetic relationship. When aligning protein sequences, a 
substitution matrix which defines the chance of occurrence of replacement of one 
amino acid to another, is used to score the aligned residues. Popular substitution 
matrices are the PAM (Point Accepted Mutation) matrices developed by Margaret 
Dayhoff [126] for scoring closely related sequences and BLOSUM (BLOck 
SUbstitution Matrix) series of matrices by Henikoff [127] for scoring of evolutionarily 
divergent sequences. In the simplest case, the alignment is pairwise, i.e. between two 
sequences. Having the scores defined, a dynamic programming algorithm can be used 
to complete the alignment in O(L
2
) time (L is the length of the longer sequence). 
Depending on the aim of the alignment, an alignment method can either be global or 
local. Global alignment finds the optimal overall alignment for two sequences, while 
local alignment identifies certain conserved regions. A general and currently still used 
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algorithm for global alignment is the Needleman–Wunsch algorithm[128]. An example 
of local alignment is the Smith–Waterman algorithm [129]. 
 
It is worth mention that a local alignment algorithm optimized using heuristic 
method, BLAST (Basic Local Alignment Search Tool) [130], is now the most used 
search tool for large sequences databases. By locating short matches between two 
sequences, although optimal local alignment cannot be guaranteed, sequences 
containing similar regions to the query can be quickly located. The great increase on 
speed compared to full alignment methods, making searches in huge genomes practical. 
It is available on the website of National Center for Biotechnology Information (NCBI) 
as a family of programs to query different type of biological sequences. 
 
When it comes to identification of conserved regions of several sequences, the 
sequence alignment task becomes multiple sequence alignment (MSA). Similarly, the 
MSA problem can also be solved by naïve dynamic programming but the time 
complexity, O(L
N
), where L is sequence length and N is the number of sequences, can 
be prohibitive. Finding the global optimum of multiple sequence alignment has been 
proven to be NP-complete [131]. Thus the commonly used MSA programs employ the 
heuristic method of progressive alignment. Although global optimum cannot be 
guaranteed, the progressive algorithm reduces the time needed to polynomial. Several 
popular MSA packages using the progressive algorithm are available, such as ClustalW 
[132], T-Coffee [133] and PSAlign [134]. For improvement of alignment speed, the 
probabilistic Hidden Markov models (HMM) were introduced and several HMM based 
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MSA methods were developed. One of these programs, Clustal Omega [135], is used in 
this work. 
 
2.2.1.2 Distance derived from multiple sequence alignment 
 
Given a set of aligned protein sequences, distances of each protein pairs can be derived. 
Apart the aforementioned PAM and BLOSUM, many substitution models are 
developed for determination of distances, such as the Jones-Taylor-Thornton model 
[136] which is an expanded version of PAM, the Equal Input Model which corrects for 
different substitution rates among different site, and the straightforward p-distance 
which derives the distance from proportion of different amino acid sites [137]. The 
p-distance is used for phylogenetic analysis in this work. 
 
2.2.1.3 Phylogenetic reconstruction 
 
Once the pairwise distances between all protein pairs are determined, a distance matrix 
is obtained. The phylogenetic relationship between all protein sequences can then be 
inferred from the distance matrix and output in form of a phylogenetic tree. This 
process is termed phylogenetic reconstruction. Based on different evolutionary models, 
various methods for generation of phylogenetic trees exist, such as the neighbor-joining 
method [138], UPGMA and maximum-likelihood trees. Neighbor-joining method was 
created in 1987, and was a greedy approximation of the balanced minimum 
evolution[139] criterion that aimed to obtain a tree with minimal length. The UPGMA 
method is essentially the aforementioned hierarchical clustering with average linkage, 
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which assumes a constant rate of evolution in the context of phylogenetic 
reconstruction [140]. The maximum likelihood (ML) method [141] uses parametric 
statistical model to estimate the probability of evolutionary events, resulting in a tree 
that is of highest probability to produce the substitution of the sequences. The ML 
method works directly on a sequence alignment, without the need of a distance matrix. 
 
Several software packages are available for phylogenetic reconstruction, such as 
MEGA [142] and Phylip [143, 144]. 
 
It is worth mention that in case of absence of multiple sequence alignment, methods 
such as DendroBLAST [145] can use transformed pairwise BLAST scores to produce 
approximation of the phylogenetic relationship between sequences in forms of 
dendrograms. 
 
2.2.2 Protein descriptors 
 
Similar to molecular descriptors, protein descriptors are quantitative values 
characterizing properties of a protein, based on primary sequences or 3D structures. As 
for functional classification and prediction, commonly used protein descriptors include 
amino acid composition, dipeptide composition [146], physiochemical properties by 
amino acid type [147] (such as hydrophobicity scale, polarizability, solvation energy of 
amino acid, residue accessible surface area) and various forms of autocorrelations of 




Once we have values protein descriptors as feature vectors, Euclidean distance can 
be used to define a straightforward measurement of distance or similarity. Various 
machine learning can also be applied for prediction of functions [151], fold recognition 
[152], protein-protein interaction [153, 154] and family classification [155, 156]. 
 
2.3 Unsupervised machine learning methods related to this 
thesis 
 
Unsupervised machine learning is a type of machine learning methods that aims to 
discover structure from unlabeled data. Unlike supervised learning methods that try to 
discover a function or mapping between the input features and the label by training data, 
unsupervised learning usually does not require a training step but tries to find out the 
intrinsic structure within the data. 
 
The unsupervised machine learning method relevant to the work in this thesis is 
clustering. The task of clustering is to group individual objects so that objects inside a 
group resembles each other and inter-group objects have lower similarity between them. 
The groups are called clusters. In order to measure similarity between objects, the 
feature of each object needs to be defined and extracted, and similarity defined and 
computed. As mentioned earlier in this thesis, various approaches defined similarity 
between biological entities such as molecules and proteins, enabling application of 
clustering methods on them. Different clustering algorithms exist for different cluster 
models. Two basic algorithms among those are to be discussed below, namely 




2.3.1 Hierarchical clustering 
 
Hierarchical clustering method aim to build a hierarchy of clusters based on 
connectivity – the similarity between objects. Hierarchical clustering can be done in 
two different strategies: agglomerative and divisive. In the agglomerative strategy, each 
object is assigned to a cluster, and cluster pairs are merged iteratively until all objects 
are in one cluster. In the divisive strategy, all objects start in one cluster and the cluster 
is divided into smaller clusters iteratively until all clusters contain one object each. In 
both strategies the hierarchy can be build, either top down or bottom up, from the 
merging and dividing events, resulting into equivalent hierarchy of objects termed the 
clustering tree. 
 
When merging into or dividing from a cluster, linkage criterion needs to be defined 
first to determine the distance between clusters based on individual object pairs from 
each cluster. Commonly used linkage criteria include complete linkage, single linkage 
and average linkage (also termed UPGMA, Unweighted Pair Group Method with 
Arithmetic Mean). These linkage criteria are defined as follows: 
Complete linkage d(A, B) = max *d(a, b): a ∈ A, b ∈ B+ 
Single linkage d(A, B) = min*d(a, b): a ∈ A, b ∈ B+ 
Average linkage d(A, B) =
1
‖𝐴‖‖𝐵‖
∑ ∑ d(a, b)b∈Ba∈A  
where d(A, B) is the distance of cluster A and B, d(a, b) is the distance between two 




We take the agglomerative strategy as example to illustrate the process of the 
hierarchical clustering algorithm. Detailed steps of the algorithm are listed below: 
 
By recording the merging events, a hierarchy of objects can be obtained. Cutting the 
clustering tree at desired level of similarity will result in a set of clusters. 
 
2.3.2 k-means clustering 
 
The classic iterative refinement algorithm of k-means clustering is the Lloyd’s 
algorithm[157]. The name k-means comes after the initial step, in which k mean values, 
i.e. centroids, which are not necessarily an actual object in each cluster, were chosen for 
desired k clusters. After initialization, each iteration consists of two steps: assignment 
step and update step, which are described below. 
 
The algorithm is said to converge when cluster assignment no longer changes. The 
result is a solution partitioning all these objects into k clusters, and is not guaranteed to 
be the global optimum. Practically a maximum number of iterations are set and the 
1 Assign each object to a cluster containing only itself, using similarity between 
objects as the similarity between clusters containing the individual object; 
 
2 Identify the closest cluster pair according to the linkage criterion and then merge 
them into a new cluster; 
 
3 Update similarities between the newly formed cluster and all other existing 
clusters; 
 
4 Repeat steps 2 and 3 until all objects are in a single cluster. 
Assignment step: each object is assigned its closest cluster, measured by the 
distance of the object to the cluster mean; 
 
Update step: calculate new means for each cluster as the new centroids. 
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algorithm is terminated if no convergence is achieved before the desired number of 
iterations. 
 
The method used for initialization may affect the final outcome. Commonly used 
methods are the Forgy method and Random Partition method [158]. 
 
2.4 Supervised machine learning methods related to this thesis 
 
Supervised machine learning is a class of machine learning methods that infers a 
function with training data including input and desired output. Such methods are 
suitable and widely used in calibrating scoring functions, both generalized and target 
specific, as the task here is to predict target values by deriving models from input 
features. Linear regression, support vector machine for regression, neural network and 
random forest are commonly used supervised machine learning methods for virtual 
screening [159], and are briefly described in the following sections with their 
advantages and limitations discussed. Choice of methods should be based on model 
performances, as well as the characteristic of the data. 
 
2.4.1 Linear regression 
 
Linear regression model assumes linear correlation between the input and output, 
which is usually the assumption used in empirical and force field-based scoring 
functions. The inputs are the energy terms for empirical or force field-based scoring 
functions, and the outputs are experimentally determined binding affinities. By fitting 
the training data, each term in the inputs are adjusted with scale factors or weights to 
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obtain best prediction in term of least squares. 
 
  Linear regression is suitable to model a wide range of linear systems. It is fast, and 
the theory associated with linear regression is well-understood, while its result is easy 
to interpret [160]. One limitation of linear regression is its sensitivity to outliers, as 
the present of outliers has great impact on the final model. Another is that linear 
regression cannot perform well on system with non-linearity [160]. 
 
 
2.4.2 Support vector machine 
 
Support vector machines (SVM) are a series of supervised machine learning methods 
used for classification and regression[161]. The input instances containing multiple 
features and a target value are considered a vector. A SVM classifier constructs a 
hyperplane in high dimensional space by identifying the vectors lying at the borders of 
different classes (which are called the support vector). Good separation is achieved by 
maximizing the distance between the hyperplane and the nearest support vectors. The 
version of support vector machine for regression is called support vector regression 
(SVR) [162]. Application of SVR in predicting binding affinity has been reported [163] 
for inhibitors of Mycobacterium tuberculosis InhA. The software used in this thesis is 
LIBSVM[164]. 
 
Support vector machine methods were first designed for linearly separable case, but 
they were then extended to work on non-linear cases by mapping the input data into a 
feature space of higher dimension with kernel functions [165, 166]. Support vector 
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machine was established on a sound theoretical foundation, and is considered robust, 
accurate and less prone to overfitting [167-170]. However, support vector machine is 
computationally expensive and requires relatively long training time [171]. 
 
2.4.3 Neural network 
 
Neural network is a mathematical tool used in machine learning. Inspired by the 
structure of biological neural networks, it usually contains an input layer, one or more 
hidden layer and one output layer. In a feed forward neural network each layer accepts 
input from its predecessor and passes the information forward. Each layer consists of 
several neurons, which is the basic unit in the model. Each neuron accepts inputs from 
neurons in the layer before it, then summarizes and passes the information processed by 
its activation function. Neural networks can be used to model complicated relations 
between the inputs and the outputs, especially when such relations are non-linear. 
 
The neural network method used in this thesis is specifically the back propagation 
feed-forward neural network [172]. Back propagation algorithm is one of the widely 
used algorithms for neural networks [171]. During its iterative model training process, 
each sample is processed and the network prediction is compared to the target value. 
The modifications to network weights to minimize the difference between the 
predicted value and the target value are then propagated backwards from the output 
layer throughout the network to the input layer [167]. 
 
Neural network can tolerate noise in the data, and can be applied when little 
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knowledge is available for the relationship between the input features and the target 
values. The downsides are that experience is required to choose a number of 
parameters empirically, and that the prediction models bear poor interpretability as 
knowledge is presented in the form of a network. Also, neural network requires long 
training time [171]. 
 
2.4.4 Random forest 
 
Random forest is an ensemble method for classification and regression. It works by 
building many decision trees at training time with each tree trained from a randomly 
sampled subset of the training samples, and the final output is taken as the mode of 
prediction from all decision trees for classification or mean for regression [173]. 
 
  A decision tree models is built through a process which iteratively splits the 
training data by finding the best separating feature among all input features at each 
level. Target value of an unknown sample can then be predicted by going down the 
splitting hierarchical of the tree and taking the value of a leaf, or mean of a group of 
leaves, depending on the pruning of the tree [174]. Random forest method uses a 
modified version of decision tree, where at each level splitting is done by finding the 
best separating feature from a subset of all features [173]. 
 
  Random forest is accurate, fast and protected against overfitting by the sampling 
process during tree growing [173]. Its major limitation is that due to the process of 














Chapter 3 Comprehensive characterization of 
biologically and therapeutically relevant 
compounds based on structural similarity 
 
 
3.1 Similarity-based characterization of compounds 
 
Similarity-based clustering and classification of compounds have been extensively 
used in diverse tasks ranging from the search of bioactive agents for drug discovery 
[6-9] to the molecular and chemogenomic studies in applications such as chemical 
space navigation and analysis [10, 11], structure-target relationship investigation 
[12-17], cross-pharmacology profiling of intra-family and cross-family targets [18, 19], 
and receptor deorphanization [20]. For facilitating the characterization of biologically 
and therapeutically relevant compounds and the orderly management of known 
compounds and the study of new compounds, it would be advantageous to organize the 
known compounds into chemical families based on structural similarity [83, 84] as well 
as molecular scaffold classification [10, 122, 176] and molecular descriptor projection 
[176, 177]. This requires a method and resource for defining, generating and 
maintaining a comprehensive set of chemical families. 
 
Characterization of large number of compounds relies heavily on automated 
algorithms for classifying large number of known compounds. Currently there are more 
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than 30 million compounds in the PubChem database [2], and among the compounds of 
functional category of interest, there are 1.4 million bioactive molecules in ChEMBL 
[178] and 760,000 patented agents in Pubchem [2]. Classification of such large quantify 
of compounds evokes two problems. The first is the difficulty to strictly use 
hierarchical clustering algorithm for grouping such a large number of known 
compounds, even though k-means hierarchical clustering algorithm is capable of 
clustering 800,000 compounds [7, 83] and none-hierarchical ones can cluster millions 
of compounds [179]. The second problem is the difficulty to systematically define 
chemical families and select family members relevant to both structural and chemical 
studies and applications in pharmaceutical, biomedical, agricultural and industrial 
research and development. These problems also arise in generating protein domain 
families, which have been resolved by selecting subsets of proteins of known functions 
as the seeds of protein domain families to both define functional and structural 
characteristics of each family and select family members by multiple sequence 
alignment against the seed proteins [41]. A similar strategy was employed for 
generating the chemical families. 
 
To make the generation of chemical families more relevant to the applications in 
pharmaceutical, biomedical, agricultural, material, and other industrial applications as 
well as to the research in chemistry and related scientific disciplines, the seeds of the 
families were iteratively selected from hierarchically clustered approved drugs, clinical 
trial drugs, investigative drugs, bioactive molecules, human metabolites, food 
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ingredients and additives, natural products, patented agents based on the 
literature-reported high-similarity measures [1, 180-182]. These families were further 
clustered into superfamilies and classes by hierarchically clustering the seeds based on 
the literature-reported intermediate similarity [16, 183, 184] and remote similarity [8, 
18, 184] measures. Although this iterative hierarchical clustering procedure seems 
similar to the incremental clustering algorithm used in selecting representative proteins 
for clustering proteins [185] and representative compounds for clustering large 
compound libraries [179], there are two significant differences. One is that the seed 
selection and clustering processes are based on hierarchical clustering algorithms. The 
second is the preferential selection of compounds of higher functional importance as 
the seeds in the order of drugs, bioactive molecules, human metabolites, natural 
products and patented agents. 
 
3.2 Generation of similarity-based seed-directed hierarchy of 
compounds 
 
3.2.1 Data collection and processing 
 
Because of the high computational cost of clustering large number of compounds, this 
work focuses on the following seven categories of compounds of functional 
significance: 1,691 approved drugs from the Therapeutic Target Database (TTD) [186] 
and Drugbank [187], 1,228 clinical trial drugs and 12,386 investigative drugs from 
TTD [186], 262,881 highly-active molecules (IC50 or Ki < 1μM against molecular 
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targets) from ChEMBL version 18 [178], 15,055 human metabolites from HMDB [188], 
80,255 ZINC processed and loaded natural products from ZINC [189], and 116,783 
patented agents from PubChem [2] databases, respectively. For database entries with 
multiple non-linked components, only the largest component was selected. Hydrogens 
were added and salt ions were removed by using Open Babel [114], and duplicates were 
identified and removed by comparing their InChIKeys, which is a hashed version of 
InChI [190] designed to be nearly unique for each individual compound with a collision 
resistance of 2.2×10
15
 [191].  
 
3.2.2 Generation of families of high similarity compounds 
 
Molecular similarity and analysis may be conducted from different structural, 
physicochemical and functional perspectives by using different types of molecular 
representations. These include molecular descriptors [176, 177, 192], molecular 
scaffolds [10, 122, 176], molecular fingerprints [8, 83, 84], and other molecular 
representations such as chemical graphs, pharmacophore patterns and molecular fields 
[193-196]. Multiple forms of chemical families can thus be generated from these 
molecular representations in a similar manner as the multiple forms of protein families 
generated from multiple-sequence alignment of protein domains [41, 42], conserved 
signature profiling of selected sequence segments [43], structure classification [44, 45] 
and combined analysis of these and other features [46]. Considering the efficiency and 
accuracy, one type of molecular representation -- the 2D molecular fingerprints 
(specifically, the 881-bit PubChem substructure fingerprints computed by using PaDEL 
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[105]) – was used for representing molecules, which was selected because of its 
computational efficiency, demonstrated effectiveness in similarity searching, and 
extensive applications in drug discovery [8, 197-201]. 
 
Seed compounds are used to define functional families, to represent certain parts of 
the bioactive chemical space for certain function. Thus seed compounds are selected 
from each subset of compounds of different functional categories while keeping in 
mind that they should cover a new part of the chemical space, compared to existing 
families. The seeds of the families were assigned and used to assemble compounds into 
families by the following iterative hierarchical clustering procedure. In the first 
iteration, 1,691 approved drugs were clustered by hierarchical clustering algorithm 
with the 2D fingerprint Tanimoto coefficient (2DF-TC) as the similarity metric and the 
complete linkage as the linkage criterion. Tanimoto coefficient was used because it is 
the most popular similarity metric for measuring compound similarity [8]. Complete 
linkage was used because of its relatively good performance in clustering bioactive 
compounds in a recent comparative study [202]. The criterion for grouping compounds 
into a cluster of high-similarity compounds is 2DF-TC >0.85, which was adopted 
because it is a widely used criterion for avoiding structural redundancy in selecting 
compound libraries for screening bioactive compounds [1, 180]. High-similarity 
compounds grouped by this criterion typically have 30%-81% chance of having the 
same activity in the same bioassay [1, 181, 182]. The drugs in each cluster were 
assigned as the seeds of an approved drug family with the family name systematically 
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characterized by the target/targets, activity type (e.g. inhibitor), molecular class/classes 
(e.g. benzisoxazole derivative) and drug names of the seeds.  
 
In the second iteration, the 2DF-TCs of the 1,228 clinical trial drugs against the 
seed/seeds of the existing families were first computed. If the 2DF-TC of a drug 
is >0.85 with respect to all the seeds/seed of a family, the drug was assigned as a seed of 
that family. If the 2DF-TC of a drug is >0.85 to some but not all of the seeds of a family, 
the clinical trial drug was assigned as a member of that family. If the 2DF-TC of a 
clinical trial drug is >0.85 to the seeds of more than one family, the clinical trial drug 
was tentatively assigned to the family with the largest 2DF-TC and the remaining 
families were marked as cousin families to the assigned families so that the cousin 
families can be subsequently evaluated for possible merger into a combined family. The 
remaining unassigned clinical trial drugs were subject to the same procedure as that of 
the first iteration to cluster them as the seeds of clinical trial drug families for 
assembling subsequent compounds into the respective families.  
 
In the subsequent iterations, each set of 12,386 investigative drugs, 262,881 
highly-active molecules, 15,055 human metabolites, 80,255 ZINC-processed natural 
products, and 116,783 patented agents were in turn subject to the same procedure as 
that of the second iteration to assign compounds into the existing families or as the 
seeds of new investigative drug families, bioactive molecule families, human 
metabolite families, natural product families and patented agent families for 
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assembling compounds into the corresponding families respectively. If the 2DF-TC of a 
compound is >0.85 to the seeds of more than one family, it was preferentially assigned 
in order of priority to approved drug, clinical trial drug, bioactive molecule (currently 
highly active molecules), human metabolite, natural product and patented agent family 
respectively. Certain functional categories such as human metabolites and natural 
products are of special interests beyond one scientific discipline. Therefore, if a 
compound from these categories (e.g. a natural product) was preferentially assigned to 
a family of a different category (e.g. approved drug), that family was marked and is 
displayed as containing compounds from this special category (e.g. approved drug 
family with natural product). 
 
The iterative process described above is illustrated in Figure 3-1, followed by a 
summary of the workflow. 
 
 
Figure 3-1 Flowchart of the seed-directed iterative clustering algorithm used in 




As illustrated in the flowchart, the first round of the whole process started with 
approved drugs. Because at the time there was no existing family to represent any part 
of the chemical space, all the approved drugs were assigned as seed compounds and 
the first batch of families were built from these seeds by hierarchical clustering. 
During the next round, a new compound set which consisted of drugs in clinical trial 
was to be added into the compound hierarchy. At this moment as there were already 
families built from seeds of the previous round, all compounds of the current set were 
“matched” based on structural similarity against seeds of existing families to decide 
membership. For those compounds which were not matched for any family, they were 
assigned as new seeds of this round as they were not structurally similar to any 
existing families, so they represented a new part of the chemical space. New families 
for this round were built from these new seeds. After this step, there were families and 
seeds of both the first and second compound sets in the hierarchy. This process was 
then repeated for several subsequent rounds, with each round incorporating a new set 
of compounds of a new functional category. In this way, all known compounds could 
be added to the chemical family hierarchy iteratively. 
 
While possible, the names of these families were systematically determined in a 
similar manner as those of approved drugs. Many clinical trial and investigative drugs 
have little molecular class information and large number of bioactive compounds and 
natural products are without a common name, which make it difficult to automatically 
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search for their molecular class names. Therefore, while possible, the IUPAC 
systematic names were used to extract common substructure names as putative 
molecular class names. Further efforts are required to determine the molecular classes 
of these families from the structure information of their seed/seeds. For the remaining 
families that retrieval of molecular class information was not possible, their family 
names were tentatively characterized by the names or external database IDs of their 
seeds. 
 
3.2.3 Generation of superfamilies of intermediate to high similarity 
compounds and classes of remote to intermediate similarity compounds 
 
The centroid seeds of the families were further clustered by hierarchical clustering 
algorithm with the 2DF-TC as the similarity metric and complete linkage as the linkage 
criterion, so that the families can be assembled into superfamilies and classes. The 
criterion for assembling families into a superfamily of intermediate to high similarity 
compounds is 2DF-TC >0.70, which was applied because compounds satisfying this 
criterion have been regarded as similar to one other [184, 203] and those with slightly 
lower similarity typically have remote similarity [183]. Compounds grouped by this 
intermediate-similarity criterion may have up to 30% chance of having the same 
activity in the same bioassay [16]. These superfamilies were systematically named 
from the common target classes, chemical classes and individual family names of the 
constituent family names. A superfamily is typically composed of compounds of the 
64 
 
same or highly similar molecular scaffolds targeting the same target, members of the 
same target subfamilies, or target sites accommodating similar molecular scaffolds. For 
instance, the cAMP-specific 3',5'-cyclic phosphodiesterase, TNF inhibitor xanthine 
derivative superfamily includes two families of xanthine derivatives against the two 
targets and three families of structurally similar purine derivatives, N-alkylguanine 
acyclonucleosides, and theobromines. 
 
The criterion for further assembling superfamilies into classes of remote to 
intermediate similarity compounds is 2DF-TC > 0.57, which was used because it can 
reasonably capture similarity compounds with cross-pharmacology relationships but 
not necessarily having the same activity [18]. A class typically consists of a large 
number of compounds that bind to multiple members of a target family or target 
families with binding sites accommodating similar molecular scaffolds, which makes it 
difficult to systematically name it. Therefore, classes were tentatively named by their 
class IDs only. Efforts will be made to manually determine their names. An example of 
a class is composed of the binders of GPCR Class A subfamilies A1 (C-C chemokine 
receptors), A9 (neuropeptide Y receptors), A13 (cannabinoid receptors), A17 
(dopamine receptors), A18 (muscarinic acetylcholine receptors) and A19 (5-HT 
receptors), cholinesterases, tryptases, dopamine transporters, and sodium channel 
proteins, etc. 
 




In order to better store and represent the chemical families generated, the compound 
similarity hierarchy which is the result of characterization of compounds by similarity 
was deposited into a Chemical Family database named CFam. The CFam Chemical 
Family database was developed both as a database of function-based chemical families 
and as a resource for facilitating further development of chemical family databases. The 
database is publicly accessible at http://bidd2.cse.nus.edu.sg/cfam . 
 
3.3.1 Data model 
 
There are four major types of entities in the database, namely molecule, family, 
superfamily and class. Each type of entity corresponds to one level in the clustering 
hierarchy. For the relationship between entities of different levels, inclusions were 
recorded as molecule in family, family in superfamily and superfamily in class, 
respectively. Cousin families were recorded separately with each record consists of 
identifiers of the participating two families. 
 
Each record in the molecule, family, superfamily and class is assigned a unique 
CFAM ID, which is an integer indicating the internal entry number prefixed by 
CFAMM, CFF, CFS and CFC, respectively, for different entity types. Since each 
molecule entry has its database of origin, the external database identifier was recorded. 
In addition, standard InChI, standard InChIkey were calculated and assigned to each 




3.3.1 Data content 
 
Entities in the CFam database include the seeds, members and names of families, 
superfamilies and classes functionally characterized by the approved drugs, clinical 
trial drugs, investigative drugs, highly-active molecules (IC50 or Ki < 1μM against 
molecular targets), human metabolites, ZINC processed and loaded natural products 
and patented agents. Table 3-1 provides the statistics of CFam seeds, compounds, 








Table 3-1 The statistics of molecules, CFam seeds, seeds with members, families, superfamilies and classes with respect to the seven functional 
categories of compounds: approved drugs, clinical trial drugs, investigative drugs, bioactives (currently highly-active molecules), human 
metabolites, zinc-processed natural products and patented agents. The number of members of these families from the two categories of special 















Approved Drugs 1691 1691 95367 (4121 HM, 19408 NP) 1114 937 813 
Clinical Trial Drugs 1228 1168 38981 (551 HM, 3258 NP) 863 756 537 
Investigative Drugs 12386 11093 93191 (4321 HM, 11881 NP) 4226 2870 1700 
Bioactives 262881 98523 171162 (833 HM, 24439 NP) 29983 15088 4035 
Human Metabolites 15055 5229 10408 (5229 HM, 1820 NP) 2058 1377 709 
Natural Products 80255 19449 20821 4017 1517 394 
Patented Agents 116783 60349 60349 44875 12335 3455 







Grouping of compounds at the family level captures the structural similarity between 
the seeds and members. Taking approved drug family CFFAD434 “cAMP-specific 
3',5'-cyclic phosphodiesterase 4A inhibitor xanthine derivative Dyphylline Family” as 
example, this family consists of three seed compounds, namely Dyphylline, 
Doxofylline and beta-hydroxyethyl theophylline, each containing a xanthine scaffold in 
the structure (Figure 3-2, structures of CFAMM00061165, CFAMM00061163, 
CFAMM00061168) with minor varieties for the side chains. Its members are 
structurally similar to the seeds (Figure 3-2, structures of CFAMM00061161, 
CFAMM00061166, CFAMM00061162) but with larger varieties in the structures. 
Cousin families such as approved drug family CFFAD2 “cAMP-specific 3',5'-cyclic 
phosphodiesterase 4A inhibitor xanthine derivative Enprofylline Family” is also a 
family of xanthine derivatives but with different structural features (Figure 3-3, 
selected seeds CFAMM00000062, CFAMM00000112, CFAMM00000056, selected 
members CFAMM00000225, CFAMM00000277, CFAMM00000093). These two 
families, CFFAD434 and CFFAD2, belong to the same superfamily CFSAD2 
“cAMP-specific 3',5'-cyclic phosphodiesterase, TNF inhibitor xanthine derivative 
Superfamily”, which consists of another xanthine derivative family CFFAD46 “Tumor 
necrosis factor inhibitor xanthine derivative Pentoxifylline Family” and other families 
from approved drugs (CFFAD90 “Theobromine Family”) or patented agents. Within 
this superfamily, three out of six families share the same target type, the 
phosphodiesterase; while another family targets the tumor necrosis factor. This is 
expected because certain type of tumor necrosis factor shares inhibitor with 
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phosphodiesterase [204]. In the class level, CFCAD2 “Class 2” is the class to which 





Figure 3-2 Selected seeds and member compounds for family CFFAD434. Seeds are in 
the first row: CFAMM00061165 dyphylline, CFAMM00061163 doxofylline, 
CFAMM00061168 3-propyl-7H-purine-2,6-dione; member compounds are in the 












Figure 3-3 Selected seeds and member compounds for family CFFAD2. Seeds are in 
the first row: CFAMM00000062 aminophylline, CFAMM00000112 enprofylline, 
CFAMM00000056 1-prop-2-enyl-3,7-dihydropurine-2,6-dione; member compounds 







3.3.2 Data access 
 
CFam is publicly accessible at http://bidd2.cse.nus.edu.sg/cfam . The database is 
accessible in three different modes from the homepage of the web interface (Figure 3-4). 
One can either search by keywords, browse by functional categories or search by 






Figure 3-4 CFam web interface. CFam is searchable by three modes: compound and 
family name and ID searching, browsing of CFam families, superfamilies and classes, 
and the alignment of a compound against CFam families.  
 
The first mode enables the search of CFam by inputting a compound name or ID, 
where the ID can be either CFam molecule ID or identifiers for external databases such 
as Pubchem, ChEMBL, ZINC, and TTD. The input keyword can also be part of a CFam 
family, superfamily or class name or ID. Search can be submitted by clicking one of the 
buttons “Molecule”, “Family”, “Superfamily” and “Class” to indicating the keyword 
type. For instance, inputting “aspirin” and then clicking “Molecule” leads to the CFam 
molecule CFAMM00072836 page which shows that aspirin belongs to the CFam 










The second mode enables browsing of CFam families, superfamilies and classes of 
any functional category, which can be selected by first clicking the “Family”, 
“Superfamily” or “Class” word in the section header titled “Browse CFam 
Family/Superfamily/Class by Functional Category”, and then clicking a specific 
functional category below the header. For instance, clicking “Family” and then 
“Approved Drug Families” leads to the page of CFam approved drug families list 
(Figure 3-6). One can also choose either to display all families, or those without 
members. Clicking family names in the list of families will lead to the pages showing 
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family information (Figure 3-7), where the family information as well as cousin 
families, seeds and members, are shown. Similarly, information of superfamilies 
(Figure 3-8) and classes (Figure 3-9) can be obtained in the same way, except the choice 
of superfamily or class is to be made. 
 
 
Figure 3-6 The CFam approved drug families browsing page resulting from the 
clicking of “Family” in the section header titled “Browse CFam 
Family/Superfamily/Class by Functional Category and “Approved Drug Families” in 















Figure 3-7 Family information showing family name, number of seeds and other 
members, functional category and the superfamily and class it belongs to, as well 







Figure 3-8 Superfamily information showing superfamily name, functional category, 
number of member families and the class it belongs to. A list of member families with 





Figure 3-9 Class information showing functional category as well as a list of member 
superfamilies. The number of member families of each superfamily is also provided. 
 
 
The third mode facilitates the alignment of an input compound in form of SMILES or 
molecular fingerprint against CFam seeds to identify CFam families with high, 
intermediate and remote similarity to the input compound. The list of up to 30 CFam 
families with at least one seed having 2DF-TC > 0.85 (high similarity family), 
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0.85≥2DF-TC > 0.7 (intermediate similarity family) and 0.7≥2DF-TC > 0.57 (remote 
similarity) to the input compound is provided. Figure 3-10 shows the result page of the 
alignment of aspirin with CFam seeds. To facilitate the development of chemical family 
databases and the structural and functional analysis of molecules, CFam seeds can be 
downloaded from the CFam main page (Figure 3-4). 
 
 







3.4 Achievements of the Chemical Family database CFam 
 
The work provided a practical and effective method to group compounds into families 
which were relevant to research and applications in drug discovery, chemical biology, 
metabolism, natural products, chemical engineering and industrial applications. By 
designing and implementing an innovative seed-directed iterative algorithm, 
compounds of very large quantity were organized into functional families based on 
structural similarity. 
 
Another significance was that, for the first time it enabled the establishment of a 
chemical family database based on similarity with functional annotation, just like the 
importance of protein family databases to protein research. It is a useful resource for 
similarity-based virtual screening applications, such as activity prediction for novel 
compounds and navigation of functional chemical space. 
 
 
3.5 Discussions and potential improvements 
 
Specialized chemical information resources such as the chemical family databases 
complement the general chemical databases for facilitating focused studies on the 
navigation, classification, and the structural and functional characterization of 
molecules. The chemical family databases that comprehensively cover the known 
chemical space and characterize molecules from different molecular representations are 
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increasingly needed given the rapidly expanding pools of molecules from synthetic and 
natural sources [205-207] and the increasing need to analyze higher number and more 
variety of compounds for diverse applications [18-20, 176]. To meet such a need, the 
CFam database needs be further updated to expand existing functional families and add 
new families of moderately-active molecules (IC50 or Ki 1-10 μM against molecular 
target), food ingredients and additives, flavors and scents, agrochemicals, natural 
products beyond ZINC processed ones, toxic substances, purchasable compounds, and 
other compounds. Although some of the CFam families are currently composed of 
seeds only, these seeds are nonetheless useful for facilitating further development of 
chemical families and function-based classification of compounds.  
 
In addition, hierarchical molecular classification based on structural scaffolds also 
captures an essential aspect of molecular structural similarity. Due to the computational 
burden as well as the popularity of molecular fingerprint based classification in virtual 
screening applications, scaffold clustering is not used for the current CFam. In future 
update and expansion, scaffold clustering can be built on the molecules in the database, 
and scaffold families can be mapped to similarity families based on fingerprints, in 
order to study and compare the difference between these two different classification 










Chapter 4 Characterization of biologically and 




4.1 Scoring functions as characterization methods of compound 
from the target structure perspective 
 
4.1.1 Current approaches in scoring 
 
Current scoring functions can be classified based on their approaches as 
knowledge-based, force field-based, and empirical scoring functions. A list of 
computational approaches among popular scoring functions is presented in Table 4-1. 
Scoring functions using the same approach may differ by their emphases as they are 





Table 4-1 Comparison of computational approaches in current scoring functions [208]. For force field-based and empirical scoring functions, additivity of the 
terms is not always guaranteed [209]. 
 
Type Computational nature Terms Advantages Drawbacks Examples 
Knowledge-based Pairwise potentials derived 
from the frequency of 
atom pairs in a database 
using the inverse 
Boltzmann relation 
Potentials of individual 
protein–ligand atom pair as a 







treatment of the 
reference state 
DrugScore, ITScore, PMF 
Force field-based physical atomic 
interactions; parameters 
from experiment and ab 
initio quantum mechanical 
calculations 
VDW interactions, 
electrostatic interactions, and 
bond stretching and torsional 
forces 
accurate Slow; treatment 
of solvent 
DOCK, AutoDock, GOLD 
Empirical Combination of a set of 
weighted simple energy 
terms; weights obtained by 
fitting a training dataset 
VDW energy, electrostatics, 
hydrogen bond, desolvation, 
entropy, hydrophobicity, etc. 










4.1.2 Generalized and target-specific scoring functions 
 
Generalized scoring functions are trained on a dataset which tries to cover diverse 
receptor and ligand families in order to perform equally well among various systems. 
The training datasets are usually selections of 3D structures from PDB [210] database 
after considering several aspects of the structures, e.g. structure source, quality, type of 
ligand, etc. There are also putative datasets for calibrating and evaluating the 
performance of scoring functions such as the DUD [211] and ZINC [212]. However, 
only one target or target group is often studied at a time. In such case concern for the 
performance of the scoring function is within such specific target group, rather than the 
general performance among diverse targets. This allows the application of target 
specific scoring functions. A target specific scoring function is trained with data only 
within the target or target group of interest, and then used to predict the binding pose 
and binding affinity of new compounds, or to screen a library for potential binders. 
Such narrowing down of the training dataset selection allows better performance on the 
target group, compared with the generalized scoring functions. This trade-off is also 
justified by a number of “no free lunch” theorems [213-215], i.e. if a solution is 
optimized to perform better over one class of problems, its performance over another 
class will be brought down. In a study assessing the performance of 37 scoring 
functions over 7 types of proteins, there is no single scoring function which excels in all 




  A possible explanation to the lack of a good performing overall scoring function for 
docked ligand poses for all target types could be the insufficient characterization of 
target specific interaction features. In most cases docking programs cannot exactly 
reproduce the binding pose of a ligand in the co-crystal structure due to the limitation of 
the sampling granularity and the uncaptured induced-fit effect. So the predicted binding 
poses for ligands without known co-crystal structures with the receptors cannot be 
assumed to be exact. Some heavy atoms of the ligand forming weak interactions may be 
misplaced, while some strong interactions such as hydrogen bond and electrostatic 
interaction are likely to be identified. Furthermore, different interaction types in a 
specific receptor family are usually contributed by certain amino acid types in the 
receptor. For example, in the case of receptor CDK2 with ligand ATP, 3 hydrogen bonds 
at the binding site are always formed among different engineered structures, 
contributed by amino acids Glu81, Phe82 and Leu83 [216]; and for c-Kit tyrosine 








Table 4-2 Comparison of selected target specific scoring functions. 
 






AutoShim[87] E+P PLS predict IC50 (pIC50) CFS1R 0.5 
 
    PDK1 0.27  
BALLDock/SLICK[217] E GA, MLR predict binding pose lectin 0.27 0.85 




[219] QSAR PLS predict pKi Thrombin 0.78  
Seifert[220] E Taboo search enrichment CDK2, ERα, COX2   
POEM[88] E DOE + ensemble regression predict binding pose kinase  2.97 
    ATPase  3.41 
SSM[221] E+RMSD Random Forest enrichment TK, ER, AChE,PDE5, and 
PPARγ 
  
DrugScoreRNA[222] KB KB docking, predict ΔG RNA-ligand 
 
 
FLAP[223] FP  enrichment FactorXa, TK, ERα   
IFS[224] FP  enrichment mGluR   
Kumar[225] P+FP Tanimoto coefficient screening TMPKmt   
TS-VS[226] Constraints+E filtering enrichment ERα   
Abbreviations: 
E -- empirical; KB -- knowledge-based; FP -- fingerprint; P – pharmacophore; 









  Several current target specific scoring functions are listed and compared in Table 4-2. 
They are optimized for various tasks, showing the feasibility of such strategy. 
 
Some review articles point out that current scoring functions are poor at predicting 
binding affinity[86], thus rescoring with other scoring functions over the poses 
generated by docking is recommended to obtain better accuracy[85]. It is also 
suggested that one rescore the poses with additional geometry-match-based scaling 
factor to scale the energy terms[227]. It is noteworthy that some empirical scoring 
functions are trained and validated over known structure for the ligand-receptor 
co-crystallization and can produce highly correlated prediction on binding affinities 
(Table 4-3). However, such kind of scoring functions are not suitable for the task of 
predicting binding affinity for compounds without known co-crystal structure, where 
the binding poses are predicted by docking programs and can be quite different from 
those co-crystal structures. 
 
Table 4-3 Selected generalized scoring functions good at predicting binding affinities. 
 
Name Scoring Approach Objective Target R
2
 
BAPPL[228] E MLR ΔG non-metallo 0.85 
PreDDICTA[229] E MLR ΔG DNA-ligand 0.9 
BAPPL-Z[230] E MLR ΔG Zinc-containing 0.77 
SFCscore[231] E+QSAR MLR pKi from AffinDB 0.72 








4.2 Development of target specific scoring approach 
 
4.2.1 Protein structures 
 
Four protein targets, cyclooxygenase-2 (COX-2), colony stimulating factor 1 
receptor (CSF1R) , epidermal growth factor receptor (EGFR) and 3-phosphoinositide 
dependent protein kinase 1 (PDK1) were selected for this study. As tyrosine kinases, 
CSF1R and EGFR are involved in various signaling pathways related to development 
and certain types of cancers, and have large numbers of structures and inhibitor 
information. COX-2 is an enzyme responsible for inflammation, and drug discovery 
efforts of non-steroidal anti-inflammatory drug (NSAID) targeting COX-2 is an active 
research field. Also CSF1R and PDK1 were studied in a previously published method 
named AutoShim [87] where target-specific scoring functions were tuned for these 
two targets respectively, thus performances of the proposed method in this study on 
these two targets can serve as references for comparison of predictive power. 
 
  The structures are collected from the Protein Data Bank (PDB) [210]. Only structures 
of co-crystallization with ligands are interested because having a bound ligand can offer 
better approximation of the conformational change upon binding. We also considered 
the resolution of the structure and used a cutoff of 2.5 Å. Both natural forms as well as 
engineered structures are included in order to achieve a better diversity. The PDB codes 
of structures used for EGFR were: 1XKK, 2ITN, 2ITV, 2RGP and 3BEL. Selected 
structures for COX-2 were 3HS5, 3NT1, 3NTG, 3QH0, 3TZI, 4E1G, and for CSF1R 
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Figure 4-1 (A) PDB code 1XKK, EGFR with ligand GW572016 (Lapatinib). 
(B) PDB code 2ITN, EGFR kinase domain G719S mutation in complex with 








4.2.2 Inhibitor dataset 
 
Inhibitors with experimentally determined IC50 values were collected from 
BindingDB [233], in addition with data manually collected from journal articles. The 
activity dataset for COX-2 had total 2347 compounds (after preparation by Sybyl [234]) 
in the dataset, whose binding affinity ranged from 0.001 nM to 60 mM, and molecular 
weight from 124 to 755 Da. For CSF1R, there were 318 ligands after preparation with 
activity ranging from 0.3 nM to 30 mM with molecular weight ranging from 210 to 583 
Da, and EGFR had total 1490 compounds, whose binding affinity ranged from 0.003 
nM to 6.5 mM, and molecular weight from 138.00 to 903.84 Da. 
 
4.2.3 Molecular docking 
 
In this study, two molecular docking programs were used, namely Surflex-dock in 
Sybyl-X [235] and Autodock4 [236]. 
 
  Before docking, active compounds of each target were preprocessed with Sybyl-X 
[234] ligand preparation tool, which filled valences, removed duplicates and produced 
a single least strained tautomer for each compound. Prepared compoundswere then 
processed with Open Babel [114] to add hydrogen atoms. Receptor structures were 
also prepared with the receptor preparation tool in Sybyl-X, where the ligands were 
extracted, water molecules removed and hydrogen atoms added. The ligand binding 
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sites were defined by the ligand in the co-crystal structure within the PDB file: in 
Sybyl-X, the binding site of each structure was generated by clipping the complex 
structure with its ligand in the vicinity of 10 Å (resulted in a “protomol”); while for 
Autodock4, the binding sites were automatically defined with the ligand in the 
complex structure. 
 
  These prepared compounds were docked to every selected PDB structures of their 
respective targets with Sybyl-X and Autodock4. For each compound, the pose with 
best docking score among all docked poses with all receptor structures used was 
selected for re-scoring. Docking scores from both docking programs were also 
recorded for comparison with the target-specific scoring function in this work, as well 
as for use as additional features for the scoring scheme used in this work. Docking 
score from Surflex-dock contained three terms: total score expressed as -log(Kd), 
crash score describing steric clash and polar score indicating contribution of the polar 
non-hydrogen bonding interactions [235]. Autodock4 output an “Estimated Free 
Energy of Binding”, along with Van der Waals interaction energy, electrostatic energy, 
total internal energy, torsional free energy and energy of unbound system. 
 
4.2.4 Re-scoring of docking results 
 
A set of empirical scoring terms were calculated including van der Waals, 
electrostatic, hydrogen bond and metal−ligand interaction energy, and also solvation 
free energy change (hydrophobic effect of the receptor), changes in conformational 
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entropy. The Amber force field [237] and Sanderson partial charges [238] were used in 
calculating the van der Waals and electrostatic interaction energy. Hydrogen bond 
interaction energy was calculated with Morse potential [239]. The hydrophobic effect 
was estimated by Eisenberg's method of atomic solvation parameters [240]. Changes of 
conformational entropy were estimated by an empirical formula [241]. 
 
  To adopt the scoring function for our new scoring scheme, the energy terms relevant 
to receptor were calculated and summed separately by amino acid types, i.e. the van der 
Waals interactions, electrostatic interactions, hydrophobic effect and hydrogen bond 
interactions. Each type of interaction term produces 20 output values for 20 
proteinogenic amino acid totaling 100 terms in addition with 3 terms: ligand-metal 
interactions, ligand-water interactions, and ligand conformational entropy change 
which were non-decomposable to amino acids, and an intercept term. The modified 
scoring function with amino acid type specific energy terms was used in the subsequent 
scoring process. 
 
To evaluating the binding affinity of docked ligands, only the top poses ranked by the 
docking software for each ligands were selected, which was assumed to be the most 
accurate prediction of the binding pose. 
 
4.2.5 Pharmacophore points interactions 
 
In order to ensure the scoring function includes important interactions between the 
ligand and the receptor, additional pharmacophore interactions were added to the score. 
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A pharmacophore is a necessary molecular feature for the interaction between a ligand 
and a receptor, which facilitates the binding of the two. In this study, we define five 
types of pharmacophore points and selected their interactions. The pharmacophore 
types used were: hydrogen bond donor (D), hydrogen bond acceptor (A), negatively 
charged (N) atom, positively charged (P) atom, aromatic (R) group. Based on the 
IDATM [242] atomic typing, an in-house program was written to assign 
pharmacophore types to atoms in the docking results. Interactions between 
pharmacophore points can be attractive, such as a hydrogen bond donor in the ligand 
adjacent to an acceptor in the receptor (DA), and vice versa (AD). Known repulsive 
interactions are NN and PP. In order to capture all possible interactions, a total number 
of 25 interaction types (five types from the ligand and five from the receptor) were 





Figure 4-2 Pharmacophore points and interactions as illustrated by PDB structure 
1XKK and docked ligand ZINC41747194. Colored balls are pharmacophore points and 
the meanings of colors are: green D, red A, blue P, white N, yellow R. 
 
4.2.6 Model fitting 
 
  The binding affinity of the used compounds in this study is given in IC50, whose 





and we also have the equation ΔG = RTlnKi, so the final conversion between IC50 and 
change of free energy is ΔG = RT[ln(IC50)-ln(1+S/Km)]. As the values of S and Km are 
often not reported, we use only the RTln(IC50) part as desired output of the data, which 
is linearly related to ΔG. Such approximation is commonly used when IC50 is the only 




  A number of supervised machine learning methods were used to build prediction 
models for binding affinity from energy terms from our amino acid type specific 
scoring function with pharmacophore point counts and docking scores. Predictive R 
squares were reported from cross validation. The methods used were: linear least 
squares, artificial neural network, support vector regression and random forest. The 
performance of each method were evaluated and compared. 
 
 
4.3 Performances for characterization of compounds based on 
target structures 
 
4.3.1 Model performances for different feature sets and their 
combinations 
 
The input features generated from the docked ligand poses for use in the scoring 
function can be grouped into three feature sets: the empirical features including atom 
pair interaction between ligand and the receptor (E), the pharmacophore features 
including all type of pharmacophore interaction counts (P), and the docking scores (S). 
To obtain the optimal predictive power and to compare models built from different 
feature sets, regression models were built on each feature sets as well as their 
combinations, and the values of test R square from ten-fold cross-validation were 
listed in Table 4-4. 
 
  Paired sample t-tests were used to compare performances of models built from 
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different feature sets. Feature set E performed better than P for all modeling methods 
(P<0.01 LS, SVR, RF and P<0.05 for NN), which was expected as feature set P 
contained counts of the interaction pairs and were not as precisely characterized by 
numerical empirical scoring terms broken down to amino acid types. Moreover, there 
was no significant difference comparing feature set E to the combination of E and P, 
which implied that no more information could be captured by feature set P. In other 
words, the empirical scoring terms were able to cover information of pharmacophore 
interactions derived from the docked structures. 
 
  In order to determine whether any improvement was achieved with the empirical 
feature set used in this study, the performances were compared between feature sets E 
and S for each modeling method. For the first and second best performing methods 
SVR and RF, the improvements for feature set E over S were significant (P<0.01for 
both), while the rest two methods LS and NN the differences were not significant. To 
compare the overall performance in predicting binding affinity between the two 
docking programs used and the target-specific empirical scoring function, the best 
performing models with RF should be compared to the LS models built with docking 
scores S, as these scores were designed to be linearly related to binding affinity. RF 
models built with feature set E performed significantly better than LS models built 




4.3.2 Comparisons of performance of modeling methods and docking 
programs 
 
The modeling method with best performance in this study was RF (P<0.01 compared 
to SVR), followed by SVR (P<0.01 compared to NN), and the performance of NN 
models were slightly better than LS in term of averaged R square, although this 
difference was not statistically significant. 
 
  The performances of models grouped by the docking program used were also 
compared. It turned out that the effect of using different docking programs, 
Surflex-Dock and Autodock4, was not significant, i.e. the quality of docking results 
from both programs were comparable. 
 
  The highest R square achieved was with RF with combination of feature sets E, P 
and S with an average of 0.4351, which was much higher compared to previously 
published satisfactory R square for the performance of a scoring function in predicting 
binding affinity, 0.32 [86]. Compared with the AutoShim method [87], which tuned 
target-specific scoring functions for CSF1R and PDK1, where the test R square were 
reported to be 0.5 and 0.27, the results in this work were comparable or better, as the 
best RF models with combination of feature sets E, P and S achieved 0.5083 for 
CSF1R with Autodock4 and 0.4904 for PDK1 with Surflex-Dock, and the differences 




Table 4-4 Model performances in terms of test R square from ten-fold cross-validation for models were built on each feature sets and their 
combinations. (Methods: LS, linear least squares; NN, artificial neural network; SVR, support vector regression; RF, random forest.) (Feature 
sets: E, empirical terms; P, pharmacophore point interaction; S, docking scores.) (Docking methods: Sybyl, Surflex-Dock of Sybyl-X; Autodock, 
Autodock 4.) 
  Sybyl_COX2 Sybyl_CSF1R Sybyl_egfr Sybyl_PDK1  Autodock_COX2 Autodock_CSF1R Autodock_EGFR Autodock_PDK1 Average 
 
E 0.1132 0.2401 0.1572 0.3312 
 
0.1519 0.2780 0.2070 0.2965 0.2219 
 
P 0.1197 0.1011 0.0724 0.1851 
 
0.1779 0.0979 0.0790 0.1891 0.1278 
LS E+P 0.1459 0.2837 0.1724 0.2759 
 
0.2069 0.3109 0.2604 0.3229 0.2474 
 
S 0.0709 0.2068 0.0365 0.3487 
 
0.1325 0.2365 0.0345 0.3926 0.1824 
 
E+S 0.1392 0.3043 0.1762 0.2896 
 
0.1871 0.2624 0.2150 0.3437 0.2397 
 
E+S+P 0.1901 0.2577 0.1883 0.3352 
 
0.2072 0.3158 0.2653 0.3580 0.2647 
 
E 0.1284 0.2703 0.1851 0.3100 
 
0.1757 0.2761 0.2056 0.2729 0.2280 
 
P 0.1406 0.1268 0.0956 0.2390 
 
0.2031 0.0840 0.1512 0.2471 0.1609 
NN E+P 0.1498 0.2980 0.1878 0.2871 
 
0.1934 0.3327 0.2665 0.3066 0.2527 
 
S 0.0819 0.2072 0.1135 0.3153 
 
0.1781 0.3207 0.1363 0.4018 0.2194 
 
E+S 0.1283 0.3061 0.2005 0.3531 
 
0.1739 0.2891 0.2183 0.3567 0.2533 
 
E+S+P 0.1431 0.3309 0.2115 0.3131 
 
0.1860 0.3286 0.2714 0.3105 0.2619 
 
E 0.2375 0.3721 0.3430 0.3956 
 
0.3037 0.4264 0.3867 0.3725 0.3547 
 
P 0.1282 0.2159 0.1747 0.2588 
 
0.1906 0.1404 0.1817 0.2052 0.1869 
SVR E+P 0.2695 0.4021 0.3500 0.3875 
 
0.3345 0.4202 0.3611 0.3226 0.3559 
 
S 0.1053 0.2151 0.1521 0.3605 
 
0.1955 0.3381 0.1731 0.4162 0.2445 
 
E+S 0.2288 0.3679 0.3401 0.3947 
 
0.3117 0.4162 0.4038 0.3791 0.3553 
 
E+S+P 0.2695 0.4031 0.3596 0.3897 
 
0.3294 0.4360 0.3701 0.3330 0.3613 
 
E 0.2438 0.4308 0.3787 0.4460 
 
0.3037 0.4451 0.3960 0.4208 0.3831 
 
P 0.2498 0.2534 0.2106 0.3260 
 
0.3088 0.1841 0.2518 0.3196 0.2630 
RF E+P 0.2982 0.4582 0.3884 0.4141 
 
0.3772 0.4872 0.4221 0.4193 0.4081 
 
S 0.1023 0.2268 0.1319 0.3913 
 
0.2027 0.3841 0.2333 0.4557 0.2660 
 
E+S 0.2646 0.4328 0.3617 0.4774 
 
0.3318 0.4652 0.4295 0.4729 0.4045 
 
E+S+P 0.3039 0.4705 0.3976 0.4904 
 




4.3.3 Difficulties in the current approach 
 
  The docking software Surflex-Dock of Sybyl-X employs an exhaustive search 
strategy when sampling the ligand position and conformation, and its ability for 
approximating the native binding pose outperforms some popular docking programs. 
However, deviation is still unavoidable in such process, and such inaccuracy, though 
small, necessitates the robustness of the scoring function. 
 
  Quality of the binding affinity of the ligand dataset also affects model performance. 
In most occasions of the inhibition assay the results are reported as IC50. The 
conversion from IC50 to deltaG through the Cheng-Prusoff equation [243] involves 
extra parameters, which are usually not reported. Such approximated conversion is 
resulted from the lack of detailed experiment settings, as well as the effort required to 
examine the ligand data one by one. The inaccuracy and noise introduced by this 
approximation may further compromise the correlation. Various studies have been 
addressing this issue, bringing forth discussions on the derivation of inhibition 
constants and suggesting alternatives or improved methods [244-246]. 
 
4.4 Potential improvements 
 
4.4.1 Improving the prediction model 
 
  As shown in the results and comparison with other work, this scoring function and the 
prediction models still have the potential to be further improved. One possible approach 
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is the refinement of the compound dataset. As IC50 values are measured with various 
experiment conditions, we can specially select a group of compounds with IC50 
measured in similar conditions to reduce noise. In the second place, as this research is 
mainly focused on drug discovery, some filters for drug-like properties can be applied 
on the ligand dataset before they are docked and scored, which will result in converged 
characteristics of the instances in the training dataset and possibly a better-performing 
model. Thirdly, some other empirical energy terms can still be considered, such as π-π 
stacking and π-cation interactions, which may compensate for the neglected 
interactions in the current model. In addition, as different docking methods employ 
different search protocol and scoring functions, other docking software can be tried out 
to find even better prediction of binding poses. Finally, the docking procedure can be 
further optimized by sampling the side chain conformations of the receptors in advance, 
leading to more accurate docking results [247]. Several packages are available for this 
task, such as SCWRL4 [248], SCAP[249] and NCN [250]. 
 
4.4.2 From target specific to target family specific 
 
  The improvements in predicting binding affinity for selected protein targets were 
encouraging. As we assumed that the most contributing amino acid types differ among 
different targets, such assumption may also hold true upon a family of receptors. The 
scoring function can be targeted to receptor families and trained to be target 
family-specific scoring function. 
 




Currently the amino acid type-based scoring function is calibrated to predicting 
binding affinity. The idea can also be applied in virtual screening, i.e. ranking the 
compounds or discriminate between binders and non-binders instead of predicting the 












Chapter 5 Two-dimensional characterization 
of G protein-coupled receptors and their 
ligands based on target binding site sequence 
similarity and ligand-set similarity 
 
5.1 Characterization of G protein-coupled receptors 
 
5.1.1 The G Protein-Coupled Receptor superfamily and its phylogenetic 
study 
 
The G Protein-Coupled Receptors (GPCRs) are a large group of proteins located on 
cell surface and are responsible for transduction of an extracellular stimulant into an 
intracellular response. These proteins share a conserved seven transmembrane (7TM) 
sequence motif where the ligand binding site is located. GPCRs are involved in 
various signal transduction events such as sense of light, odor and taste, 
neurotransmission, hormone signaling and cell-cell communication. 
 
Being one of the largest families in the human genome[251] with over 800 members 
identified [252, 253], the GPCR superfamily are large in number , diverse in sequences 
at the ligand binding site, and targeted by large number of ligands of different chemical 
nature including peptide, ions, amines, adenosines and lipids, etc.[19]. Thus, in order to 
facilitate characterization of different GPCRs, identification of novel GPCRs and 
deorphanization of existing GPCRs, classification and phylogenetic study of GPCRs 
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has been of considerable interest [252, 254-258]. These methods based on ligand 
binding mode as well as structural and physiological features, with both alignment and 
alignment-free approaches. Frequently used classification systems include the A, B, C, 
D, E, F clan system [254] and the GRAFS system [252]. The former is designed to 
cover GPCRs from both vertebrates and invertebrates, and not all clans are present in 
human. The latter studied only GPCRs in human and is of greater value for human 
disease mechanisms and drug discovery. 
 
The name GRAFS stands for the five main families into which more than 800 human 
GPCR sequences are clustered into 5 families: glutamate, rhodopsin-like, adhesion, 
frizzled/taste2 and secretin. Detailed information of these families can be found in 
Table 5-1. 
 
The GRAFS system was based on phylogenetic analysis on the sequences truncated 
to include only the conserved 7TM domain. The truncated sequences were then 
permuted to overcome the effect of input order of sequences on the alignment. For each 
permutation, the sequences went through alignment and bootstrapping, and finally tree 
generation with neighbor-joining method. The final tree is the consensus of all trees. 





Table 5-1 Selected GPCR members and functions for each family. The numbers of members are the numbers in human genome as of year 2014. 
 
Family Name Number of Members  Selected Functions Selected Members 
Glutamate 22 modulation of synaptic plasticity 
[259]; sweet taste sensing [260] 
Metabotropic glutamate receptor 1 (GRM1), extracellular 
calcium-sensing receptor (CASR), taste receptor type 1 
member 1 (TAS1R1) 
Rhodopsin-like 296 (not including 
olfactory receptors) 
widespread functions include sense of 
extracellular hormones, 
neurotransmitters, and light 
Rhodopsin (RHO), 5-hydroxytryptamine receptor 1A 
(HTR1A), neuropeptide Y receptor type 1 (NPY1R) 
Adhesion 33 immune repsonse [261]; neuron 
development [262] 
EGF-like module-containing mucin-like hormone 
receptor-like 2 (EMR2), G-protein coupled receptor 126 
(GPR126) 
Frizzled/Taste2 36 bitter taste sensing [263]; embryonic 
development, tissue and cell polarity 
[264] 
Taste receptor type 2 member 1 (TAS2R1), frizzled-1 (FZD1) 
Secretin 15 response to peptide hormones [265, 
266] 







5.1.2 Rhodopsin family and its clinical significance 
Being the largest family of GPCR, Rhodopsin-like receptors have gain great attention 
due to their participation in a wide range of physiological process and involvement in 
various types of diseases, while still being relatively close in binding site similarity. 
The Rhodopsin like receptors has been the focus of drug discovery. There are total 92 
receptors of this family with FDA-approved drugs (data from Therapeutic target 
database [186]. Till year 2005, 26.8% FDA-approved drugs target Rhodopsin family 
GPCRs [267]. Among the top 100 best-selling drugs, more than 20 target the 
Rhodopsin family as of year 2001 [268] with indications for diseases such as 
hypertension, allergies and asthma. Thus the Rhodopsin family receptors are 
considered highly potent for drug discovery. 
 
5.1.3 Sequence-based and ligand-based classification studies for 
Rhodopsin family 
 
Phylogenetic studies focusing on sequence feature for Rhodopsin family have proposed 
several classification system, the frequently cited one was the 19 subgroups system 
[269] based on sequence similarity, in which receptors with similarity functions were 
group together. Further studies focused on target deorphanization and ligand-based 
target characterization, so efforts were devoted to obtain accurate analysis on the ligand 
binding site, rather than on the relatively large 7TM domain with length of a few 
hundreds amino acid residue. Researches aiming to identify the ligand binding site have 
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proposed different set of residues on the target, namely the reference set. For example, 
the Novartis reference set covers ligand binding sites of aminergic receptors with 20-25 
residues [270]; Hoffman-La Roche reference set covers the 7TM pocket of Rhodopsin 
family with 28 residues [271]. The reference set used in this study is the GSK reference 
set [256], which is based on analysis on the 7TM pocket of crystal structures of 
Rhodopsin family and characterizes pharmacological relationships while minimizing 
evolutionary influence from non-ligand-binding residues. The resulted phylogenetic 
tree based on this reference set has a tendency to group receptors with same 
endogenous ligand types together. 
 
On the other hand, ligand set based characterization of the Rhodopsin family has 
revealed links between targets by the characteristics of their ligands, both within the 
Rhodopsin family [256] and with targets from other families [19]. Such efforts 
complement the sequence based phylogenetic analysis and uncover relationships 
among targets that are otherwise not obvious, and facilitate ligand repurposing, ligand 
design with desired activity profile as well as target deorphanization [20]. 
 
 
5.1.4 Recent advancement in target sequence similarity and ligand-set 
similarity based characterization of GPCR and scope of this work 
 
Characterization of protein families based on ligand set similarity is a promising 
approach in chemogenomic analysis [20, 89-91] and pharmacological classification [18, 
19] of target families, thus facilitates target deorphanization and ligand discovery [19, 
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89-92]. In such characterization efforts, relationship between targets can be established 
by ligand-set similarity (LSS) [19] or ligand-framework similarity (LFS) [20]. 
Ligand-set similarity between two targets can be defined as the summarized similarities, 
calculated by their physiochemical descriptors or substructure fingerprints, between all 
possible ligand pairs of ligand set of the two targets, and such summarization can be 
naïve summation or average, or complicated statistical method such as the Similarity 
Ensemble Approach (SEA) [272]. Ligand-framework similarity tries to mine the 
frequently-occurring substructures of ligand sets between targets in order to capture the 
difference of targets in terms of their favorable ligand scaffolds [20]. From the target 
aspect, the characterization of target-site sequence similarity (TSS) revealed the 
phylogenetic relationship between targets, which guided the classification and 
deorphanization of targets. For example, target-site sequences of GPCRs were studied 
extensively, leading to the widely adopted GRAFS classification system and numerous 
efforts for ligand discovery and target deorphanization [19, 69, 252, 254-258]. These 
three methods together captured the primary association of targets which aided in the 
chemogenomic analysis of targets of interest. 
 
There are cases the above methods are not enough to reveal secondary connections 
between targets, usually due to the diversity and minority of ligands these connections 
are based on. For instance, the members of GPCR superfamily muscarinic receptors 
have been linked to receptors of different endogenous ligands within the superfamily, 
such as certain neuropeptide, chemokine and biogenic amine receptors by LSS method 
[19], opioid and chemokine receptors by LFS method [20] and biogenic amine, 
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melatonin, and melanocortin receptors by the TSS [19, 20] method. These 
observations can be justified that some muscarinic receptors and the primarily 
associated targets share ligands of the same molecular scaffolds. In addition, chemical 
analogs of the same molecular scaffolds are also known to interact with muscarinic 
receptors as well as those receptors deemed distantly related by the LSS, LFS and TSS 
methods.  
 
The work described in this thesis is inspired by the insufficient coverage of 
secondary target associations. There is a need to comprehensively capture both primary 
and secondary target associations to facilitate the application of chemogenomic 
approaches for ligand discovery, such as scaffold hopping [52-55], target hopping [56, 
57], and polypharmacology [47-51]. In this work, a combinatorial method linking 
target-set sequence similarity [20, 69, 92] with structural fingerprint [93, 94]based 
ligand similarity was used to derive a two-dimensional target-site sequence similarity 
and ligand-similarity (2D-TSSaLS) characterization for human GPCRs and their 
ligands. Comprehensive characterization of compounds activity profiles as well as  
unexpected target associations which were neglected by previous methods was 
achieved, focusing on potential interest of applying chemogenomic approaches 
including scaffold hopping, target hopping and polypharmacology for ligand discovery 
and target deorphanization. Experimental assays were conducted to validate the 
predicative ability of the 2D-TSSaLS method for identifying new associations between 




5.2 Two-dimensional characterization method of GPCRs and 
their ligands 
 
5.2.1 GPCR sequence collection, binding site identification and 
phylogenetic analysis. 
 
The sequence of 296 human GPCR Rhodopsin family members were obtained from 
UniProt [253], The target sites of the members of this family have been defined by the 
GSK reference set of residues at the transmembrane ligand-binding sites [256]. For 
GPCRs included in the GSK reference set, the ligand-binding site residues were 
directly extracted from the set. For the remaining GPCRs, their sequences were first 
aligned against the reference set by using Clustalw Omega [135] and the residues 
mapped to the GSK reference set residues were subsequently chosen as the binding 
site residues. The sequence segments covering the binding site residues were used for 
generating a TSS phylogenetic tree, with the pairwise sequence distances computed 
and the UPGMA phylogenetic tree generated by using the MEGA 5.1 [142] software. 
The derived TSS phylogenetic tree was rendered in radical form by using an R 
package APE [273] with colored leaf nodes indicating the chemical type of 
endogenous ligands for each GPCR. The nomenclature of each receptor is based on 
gene name recorded in the UniProt database to eliminate confusions among different 
names used historically for each receptor.  
 




A total of 77,370 ligands of 184 GPCRs in the Rhodopsin family with activity values 
(IC50, Kd, Ki, EC50) < 10μM were collected from CHEMBL version 18 [178] with 
an additional requirement that the relevant records are from published literatures. 
Based on the information from the Therapeutic Target Database [186] and DrugBank 
[187], there are 538 approved, 151 clinical trial and 3115 investigative drugs targeting 
157 GPCRs in the Rhodopsin family, which were added into the ligand set. In 
processing these ligands, hydrogens were added and salt ions were removed by using 
Open Babel [114]. Duplicate compounds were identified and removed by comparison 
of their InChIKeys, which is a hashed version of InChI [190] designed to be nearly 




The Pubchem 881-bit molecular fingerprint [2] of each ligand was computed using 
PaDEL version 2.18 [105], and its molecular scaffold was extracted by using the 
Murcko decomposition method [74] implemented in RDKit [115]. The extensively 
used hierarchical clustering algorithm [8, 184] was used to cluster the ligands into 
ligand set (LS) clustering trees with the similarity metric of the Tanimoto coefficient 
[117] and complete linkage. Because of the practical difficulty in displaying and 
visualizing the 2D-TSSaLS graph of the 77,370 ligands with respect to 184 targets, 
highly similar ligands (Tanimoto similarity coefficient > 0.85) of the same molecular 
scaffold were combined into scaffold-subgroups, so that the dendrogram of the LS 
clustering tree displays significantly less number of leaf nodes. As a result, the 77,370 




5.2.3 Generation of two-dimensional target-ligand interaction graphs 
 
The 2D-TSSaLS graph shows the distribution of the ligands with respect to their 
targets (the dots) with the dendrogram of the target TSS phylogenetic tree and 
dendrogram of the ligand scaffold-subgroup LS clustering tree displayed on the 
left-hand side and top side respectively. Each dot in the graph represents a 
scaffold-subgroup with its y coordinate represents the projected location of a target of 
the scaffold-group in the dendrogram of the TSS phylogenetic tree, while the x 
coordinate represents the projected location of the ligands of the scaffold subgroup in 
the dendrogram of the LS clustering tree. In order to ease display and manipulation, the 
whole graph was split into subgraphs with the separations defined by major branches of 













5.3 Characterization results 
 
5.3.1 Phylogenetic analysis of rhodopsin-like GPCR based on target 




The computional method used in this work was previously described and used for 
analysis of 143 rhodopsin-like GPCR sequences [19]. In order to ensure the 
equivalence of our method, the phylogenetic tree of previously studied 143 
rhodopsin-like GPCRs is replicated and turned out to be the same as previously 
reported, as seen in Figure 5-1. Based on the same method, a more comprehensive 
phylogenetic tree of rhodopsin-like GPCRs consists of 296 sequences which were all 
rhodopsin-like GPCRs except the olfactory receptors available in the UniProt database, 
was generated (Figure 5-2). 
 
GPCRs tend to group by their subfamilies. For example, serotoninergic receptors, 
adrenergic receptors, dopaminergic receptors, histamine receptors as well as the trace 
amine-associcated receptors are all bioamine receptors and appear in adjacent branches, 
and closely neighbored by muscarinic receptors whose ligands contain quaternary 
ammonium cationsamine group. Other receptor subfamilies such as adenosine 
receptors, chemokine receptors, opioid receptors and sphingosine-1-phosphate 
receptors, all have their members grouped together respectively. From a more 
coarse-grained level, receptors of same endogenous ligand types were closely related to 
each other, implying consistency with ligand type organization of GPCRs. 
 
Compared to phylogenetic tree previously reported in Figure 5-1, newly added 
sequences were placed in vincinity of their respective receptor subgroups, proving the 






Figure 5-1 Phylogenetic tree of 143 rhodopsin-like GPCR used in a previous study 
[19]. Similar method is used to replicate the phylogenetic tree previously reported. 
Colors of leaf nodes indicate the chemical types of their endogenous ligands: blue for 
bioamines, dark blue for purinergics, light blue for adenosines, green for lipids, black 








Figure 5-2 Phylogenetic tree of 296 rhodopsin-like GPCRs used in this study. Colors 
of leaf nodes indicate the chemical types of their endogenous ligands: blue for 
bioamines, dark blue for purinergics, light blue for adenosines, green for lipids, dark 
yellow for peptides, gold for melatonins, purple for retinal and red for orphans. 
 
 
5.3.2 Interest of ligand discovery observed from two-dimensional plots of 
ligand-target interactions 
 
The two-dimensional interaction plots provided useful resource for investigation of 
potential drug repurposing, ligand discovery and target deorphanization. Compound 
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subgroups along the x axis were connected continuous structural variation between 
adjacent groups, with exception that at the separation of two branches of higher level of 
the clustering tree, the structures of the subgroups at both sides of the separation may 
different significantly. Similar situations were expected from the y axis of phylogenetic 
tree of rhodopsin-like GPCRs. According to the principle similarity, similar 
compounds bind to similar targets, which can be observed in the plots as enriched 
points in certain regions. However, there are situations that one molecular scaffold is 
active against a broad spectrum of targets and that large structural variations in 
compound structures result in no or minor target changes. These observations provide 
clues of potential areas for ligand discovery with different chemogenomic approaches, 
which are discussed in the following sections. 
 
5.3.2.1 Structural features of compounds of polypharmacology 
 
In the two-dimensional interaction plots, scaffold subgroups with multiple targets were 
often observed within certain target subclasses, such as dopamine receptors, serotonin 
receptors and muscarinic receptors. These activity records are usually resulted from 
unsuccessful efforts to design selectivity inhibitors for the respective subclass. Such 
cases are examples to avoid when selectivity is desirable, and derivatization of such 
compounds may result in novel selective inhibitors. In other cases, certain scaffold 
subgroups were found to inhibit targets from different subclasses, providing valuable 




One case of cross-subclass inhibitor scaffold subgroups observed is scaffold 
subgroup 4438_1117 which contains compounds CHEMBL114484 and 
CHEMBL146054. This scaffold subgroup targets 14 GPCRs from serotoninergic, 
adrenergic, muscarinic, dopaminergic and opioid receptor subclasses. 
Two-dimensional interaction plot for scaffold subgroup 4438_1117 is shown in Figure 
5-3. The structures of compound within this and adjacent scaffold subgroup are listed in 
Table 5-2. Compound CHEMBL114484 was previously reported in a pharmacological 
profiling study of CNS related receptors [274], and contributed to the activities to all 
target subclasses for the scaffold subgroup. From pharmacophore analysis of the target 
subclasses, structural features of this compound explaining its polypharmacology can 
be observed and identified. As previously reported, pharmacophore models of 
serotoninergic [275], dopaminerginc [276], adrenergic receptors [277, 278] and opioid 
receptors [279] all shared similar geometrical arrangements of hydrogen bond 
acceptors, aromatic groups and a basic tertiary amine centers, in accordance to the 
structure of CHEMBL114484. The pharmacopohore model of muscarinic receptors 
[280] showed different relative position of the hydrophobic group to the aromatic ring, 
which partly explained the relatively low affinity to muscarinic receptors. With 
difference of only one methyl group, CHEMBL146054 was reported in a search for 
opioid receptor inhibitors [281] to be non-selective. 
 
As shown in Table 5-2, scaffold subgroups within the same similarity cluster as 
4438_1117 displayed structural difference of different extent. They share parts of the 
activities of scaffold subgroup 4438_1117, depending on their structural variations. 
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Derivatives of these neighbor scaffold subgroups may be investigated for potential 
polypharmacology and reposition of bioactive compounds. 
 
Multi-targeting scaffold subgroups appear in the plots as dotted vertical lines. There 









Figure 5-3 Part of two-dimensional interaction plot for scaffold subgroup 4438_1117. 
Dots along the vertical line to the left are activity records for the compounds in this 
subgroup. Targets corresponding to the position of the dots are circled on the target 











Table 5-2 Selected compound structures of scaffold subgroup 4438_1117 and its 
neighbors within the same similarity cluster. 
 


















5.3.2.2 Patterns of structural changes of compounds for scaffold hopping 
 
Scaffold hopping is a useful strategy to discover novel active scaffolds based on known 
active scaffolds. In the two-dimensional interaction plots, consecutive horizontally 
arranged dots were observed. There are cases where several horizontal lines of dots 
neighboring each other, which indicates a series of active scaffold groups against a 
target subclass. Such observations were of great interest to scaffold hopping strategy 
because they provide actual examples of how a scaffold can be modified while 
retaining activity. 
 
  A series of scaffold subgroups which are active against the adenosine receptor a2a are 
discussed to illustrate the usefulness of the plots. The positions of these consecutive 
horizontal dots are illustrated in Figure 5-4. Selected compound structures of each 
scaffold subgroups are shown in Table 5-3 in order of appearance from left to right. 
Adenosine is the endogenous ligand of adenosine receptor a2a, which is responsible for 
regulating myocardial blood flow [282]. The selected scaffold subgroups are from two 
similarity clusters with similarity cutoff of 0.85 measured by Tanimoto coefficient of 
fingerprints, and the two clusters are number 6639 and 6640. For scaffold subgroups of 
cluster 6639, as shown in Table 5-3, every structure contains the adenine (CID 190) 
moiety as in adenosine, connected to a furan group (CID 8029) with a hydrogen bond 
acceptor resembling the ribose moiety in adenosine. Mild variations of side chain 
groups do not affect the ability of binding. For similarity cluster 6640, the situation is 
similar that the core pharmacophores persist while variations on the side chains occur. 
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Scaffold hopping strategy is exemplified by the change of these structures. For example, 
among structures in cluster 6639, methyl is replaced with cyclopropyl on a connector 
nitrogen atom, as those are both small hydrophobic groups; and for structures in cluster 
6640, the terminal piperidine moiety replaced by morpholine, demonstrating with a 




Figure 5-4 Part of two-dimensional interaction plot for scaffold subgroup from 
6639_2548 to 6641_2509, which are all active against adenosine receptor a2a. Dots 
along the horizontal red line are activity records for these subgroups. Targets 







Table 5-3 Selected compound structures of scaffold subgroup formed 16 consecutive 
dots in the plot targeting adenosine receptor a2a. Scaffold subgroups range from 
6639_2548 to 6641_2509. Adenosine, as the endogenous ligand of adenosine receptor 
a2a, was added at the first row. 
 











































  Another example is a series of scaffold subgroups targeting the cannabinoid receptor 
type 2, whose endogenous ligand is 2-arachidonoylglycerol. These scaffold subgroups 
are found to form a horizontal line in the plot (position in plot not shown), and within 
these subgroups two of them show the application of ring open and closure technique in 
scaffold hopping (as shown in Table 5-4). One of the methoxy groups of compound in 
subgroup 8845_8053 was changed to form a fused ring system with the neighboring 








Table 5-4 Selected compound structures of scaffold subgroups targeting the 
cannabinoid receptor type 2. These two scaffold subgroups within the same similarity 
cluster form an example of scaffold hopping technique ring open and closure. 
 







5.3.2.3 Patterns of structural changes of compounds for target hopping  
 
Applying modification on compound scaffold may sometimes result in decreased 
activity towards its target but novel activity against another target. Such target hopping 
strategy is often used for ligand discovery when active compounds against close related 
targets are available. Such cases appear in the two-dimensional plots as diagonal 
arrangement of dots. As an example, the area shown in Figure 5-5 is discussed. 
 
  The scaffold subgroups in this area target niacin, muscarinic and adenosine receptors, 
and their structures are shown in Table 5-5. The scaffolds of similarity cluster 7016 
targeting niacin receptors share a benzoic acid moiety resembling the niacin structure. 
The two compounds were reported to be full agonists [283]. Compared with cluster 
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7016, scaffolds in cluster 7017 have the benzoic acid moiety substituted at both sides, 
resulting in several different complex scaffolds that match the pharmacophore model of 
muscarinic receptors, which is a hydrogen bond acceptor center connected to an 
aromatic ring neighbored by hydrophobic groups [280]. Based on similar central 
structure with hydrogen bond acceptor nitrogen atoms, scaffolds in cluster 7023 have 
smaller volume and hydrophobic terminal aromatic rings, which fit into the 
pharmacophore model of adenosine receptor inhibitors xanthine derivatives [284], 
explaining the transition of targets. 
 
It is clear that from the above observation, target hopping requires knowledge of 
pharmacophore model of the desired target. By changing the structure towards 







Figure 5-5 An area from the two-dimensional interaction plot for closely neighboring 
scaffold subgroups targeting niacin receptors, muscarinic receptors and adenosine 
receptors, respectively. Dots within the red circles are activity records for these 













Table 5-5 Selected compound structures of scaffold subgroups of similarity clusters 
7016, 7017 and 7023 targeting niacin, muscarinic and adenosine receptors, 
respectively. 
 



































5.3.3 Experimentally validated activity of novel scaffold inspired by 
two-dimensional characterization 
 
Manual examination was performed on ligand structures of areas rich in activity 
records on the plots for selected targets. Among those, a series of scaffolds with highly 
similar DABCO and quinuclidine substructures were found to be active against 
serotonin receptor 4 (structures 1 through 5 in Table 5-6). These two substructures are 
rarely found in our ligand dataset, thus it is possible to obtain novel ligand scaffolds 
with structural modification of these ligands. As there are existing scaffold subgroups 
targeting both serotonin and dopamine receptors, it is possible to modify the structure 
of a serotonin receptor inhibitor to achieve target hopping to dopamine receptors, or to 
be active against both receptor subclasses. After comparing structures in Table 5-6 with 
pharmacophore models of dopamine receptors [276, 285], a series of compounds with 
the DABCO substructure connected to compact aromatic ring with hydrogen bond 
donor and acceptor were selected a vendor catalog. Preliminary binding assays 
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identified one of them, compound 1, to be active against several dopamine receptors 
and serotonin receptor 2A at micromolar level (as shown in Table 5-7). The structure of 




Table 5-6 Structures with DABCO and quinuclidine substructures which were found to 




















Table 5-7 Activities of compound 1 against selected dopamine and serotonin receptors. 
DRD1, DRD3, DRD4: dopamine receptor 1, 3, 4; 5HT2A: serotonin receptor 2A. 
 
Target Activity 
Average of all 
activities for 
this target 
DRD1 38,000 nM 705.91nM 
DRD3 23,000 nM 652.55nM 
DRD4 37,000 nM 561.16nM 






5.4 Potential improvements 
 
5.4.1 Pharmacophore analysis for elucidation of mechanisms of 
observations in this work 
 
Pharmacophore analysis has been widely used in virtual screening and ligand 
characterization [286-288]. Structural features critical for interaction against protein 
targets can be extracted and used to elucidate the mechanism of binding. In different 
types of structural modifications applied in chemogenomic approaches for ligand 
discovery or repositioning, change of pharmacophore type or positions can result in 
different activity profiles. In this work, we focus on the patterns of structural changes of 
compounds. For further investigation of the mechanisms of activity profile change 
related to the structural changes, pharmacophore alignment of the structures of interest 
against the pharmacophore model of various targets should be analysis to expand the 
understanding of those observations described in previous sections. 
 
5.4.2 Scaffold based approach for potential scaffold hopping 
identification 
 
Scaffold hopping usually results in the separation of novel and original scaffolds into 
different similarity groups, making them hard to identify from the two-dimensional 
interaction plots. Similarity method based on scaffold may solve this problem by 
grouping similar scaffold together [122-124]. However, popular scaffold based 
hierarchical characterization methods of compounds have developed various rules for 
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determination of scaffold hierarchy, making it hard to compare the accuracy and 
performance among different methods. Definition of molecular scaffold with graph 
theory has resulted in quantitative similarity value, but such approaches can require 
large computational cost. There is a need for robust and stable algorithms for further 







Chapter 6 Cross-linking biomarkers and 
targets with disease codes to facilitate 
personalized medicine 
 
6.1 Integration of information of targets, biomarkers and drugs 
by disease to facilitate personalized medicine 
 
Apart from development of methods for virtual screening, it is also important to link 
information and knowledge generated in research in therapeutic agents to the fields of 
diagnostics and theragnostics, thus to facilitate the application of such knowledge 
towards personalized medicine. Entities in therapeutics and diagnostics include targets, 
biomarkers, drugs and diseases, whose information can all be linked together by 
disease. 
 
  Personalized medicine integrates unique clinical, genetic, genomic and 
environmental information of each patient to achieve precise and individualized 
treatment and prescription [289]. Thus one important aspect is to precisely define 
each disease condition based on individual differences, where biomarkers play a vital 
role in disease subtyping. A biomarker is defined as “a characteristic that is 
objectively measured and evaluated as an indication of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” [290]. 
Biomarkers are useful in disease diagnostics and prognostics, as well as determination 
of disease subtypes and classification of patient subpopulation [291], providing 
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information for characterization of disease heterogeneity of each individual patient. 
 
On the other hand, access and application of information and knowledge of targets, 
biomarkers and drugs for personalized medicine require a disease coding system 
which codes disease conditions unambiguously. One such disease coding system is 
the International Classification of Diseases (ICD) [292]. ICD is one of the most 
widely used standard disease classification system for defining, studying and 
managing diseases and treatments [292], which is developed and curated by the World 
Health Organization (WHO). The classification of disease in ICD is based on the 
organ and tissue systems which are affected by the disease, paralleled by the 
pathogenic or molecular causes describing systematic diseases. Various symptoms, 
injuries by external causes, treatment and historical health events are also included. 
The current ICD version is ICD10 version 2010, while ICD9 is still widely used and 
ICD11 in development. 
 
The ICD system organizes diseases hierarchically based on the aforementioned 
features and codes them into alphanumeric identifiers by manual curation. ICD 
employs three levels in its classification system with the lowest level indicates the 
basic disease unit. A typical path of the hierarchy looks like this: first level “V Mental 
and behavioural disorders”, second level “F30-F39 Mood [affective] disorders” and 
third level “F30 Bipolar affective disorder”. Under each basic unit, subunits are 
defined by particulars of symptoms.  
 
Linking ICD codes of diseases to biomarkers, as well as targets and drugs 
135 
 
enables easy cross-links to bioinformatics resources for genomic and functional 
information, and provides a useful resource for implementation of personalized 
medicine. This result was presented in the recent update of the Therapeutic Target 
Database [186]. 
 
6.2 Data collection and curation 
 
Disease indications for biomarkers, targets and drugs were extracted from TTD. A 
computer program was created to automatically match the disease names to those of 
the basic units in ICD9 and ICD10. As indication data were derived from literature of 
various sources, several different descriptions for the same condition may exist. All of 
the matches were manually inspected to unify different descriptions of the same 
disease, fix ambiguous names and correct errors from the automatic matching process. 
The final matches between ICD identifiers and disease names were mapped back to 
biomarkers, targets and drugs and populated into the database. As results, there were 
1,755 biomarkers, 893 targets and 5,697 drugs mapped to ICD identifiers by their 
disease indications. Furthermore, external identifiers from biological databases such 
as UniProt [253], GeneBank [293] and Gene Expression Atlas [294], were linked to 
biomarkers, targets and drugs. 
 
6.3 A resource for facilitating the implementation of 
genomics-informed personalized medicine 
 
Information of biomarkers, targets and drugs linking to ICD identifiers can be 
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accessed at http://bidd.nus.edu.sg/group/ttd/ttd.asp . It is possible to search the 
database for diseases, targets and drugs with ICD identifiers, in addition to drug and 
target names which were previously available. ICD identifiers uniquely identify 
diseases and symptoms without ambiguity, thus are able to standardize diseases 
references, providing a fast and accurate way of navigating the database. To facilitate 
the searching of the database by ICD identifiers, links organized in cascade lists were 
developed for both the ICD9 and ICD10 systems. By navigating through the disease 
hierarchy, one can easily locate the disease of interest and retrieve relevant 




Figure 6-1 Part of the cascade lists for ICD10, showing basic units under first level 
category “C00-D49 2. Neoplasms” as an example. 
 
 
The result of searching an ICD identifier for biomarkers is a list of all biomarkers 
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related to the disease indicated by the ICD identifier. Part of the search result for 
searching with ICD identifier C43 for malignant melanoma of skin is shown in Figure 
6-2. Information on biomarkers, diseases and related targets and drugs are listed, with 









6.4 Towards a more refined disease classification system for 
personalized medicine 
 
Current ICD classification system organizes diseases based on symptoms and the part 
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of the body where the symptoms are found. Such classification of diseases ignored the 
most important information for diseases in the modern targeted therapeutic paradigm 
for medicine – the molecular mechanism of the disease identified by biomarker and 
target status. Without molecular information, it is impossible to precisely define a 
disease condition for a patient with this coding system, leading to a hindrance for 
personalized treatment and prescription. One example is the classification of breast 
cancer as illustrated in Figure 6-3. In ICD9, ICD10 and ICD11, subclasses of breast 
cancer are defined by their location in the body. 
 
 
Figure 6-3 Classification of breast cancer in ICD9, ICD10 and ICD11. 
 
  However, from the aspect of diagnosis and treatment, breast cancer can be 
classified by its molecular status into four subtypes: basal-like, luminal A, luminal B 
and HER2+ [295]. In a recent study, HER2+ breast cancer was found to be 






heterogeneous and could be further divided into HER2E-mRNA-subtype and 
luminal-mRNA-subtype based on gene expression analysis [296], as summarized in 
Figure 6-4. Thus it would create a precise disease coding system if the ICD codes 
were combined with target and biomarker identifiers from biological databases. 
 
 
Figure 6-4 Molecular subtypes of breast cancer. 
 
Breast cancer is not the only disease requires more refined classification. 
Classifications of diseases with information on biomarkers and targets available can 
all be refined. Figure 6-5 illustrates the coverage of clinically used biomarkers and 
successful targets on the disease classification system of ICD10. For disease 
conditions with plenty available biomarkers and targets, such as diseases related to 
infections, neoplasms, circulatory system and childbirth can also be refined based on 
molecular status to achieve precise disease classification for application in 
personalized medicine. 
 
Classification by receptor status
Basal-like (Triple Negative): ER-, PR- and HER2-
Luminal A: ER+ and low-grade
Luminal B: ER+ but often high-grade
ERBB2/HER2+:  amplified HER2/neu
HER2E-mRNA-subtype
(higher expression of RTKs including 
FGFR4, EGFR, HER2, as well as genes 
within the HER2 amplicon such as 
GRB7, TP53 mutation)
luminal-mRNA-subtype
(higher expression of luminal 
cluster of genes including 
GATA3, BCL2 and ESR1, 
GATA3 mutation)




Figure 6-5 Numbers of recommended or clinically used biomarkers and successful 






Certain infectious and parasitic diseases
Diseases of the circulatory system




Chapter 7 Concluding remarks 
 
7.1 Major findings and contributions 
 
In this thesis, various aspects of the implication of principle of similarity in virtual 
screening were investigated and demonstrated with chemogenomic approaches. The 
concept of similarity was emphasized throughout the whole thesis, which consists of 
the similarities of three key components: compounds, targets, and their interactions. 
Starting from similarity between compounds, chemical space can be organized and 
mapped with known compounds of interest, which in this case, approved drugs, clinical 
trial drugs, investigational drugs, biologically active compounds and compounds of 
other functions related to biomedicinal research. Attempts of optimization were also 
carried out for scoring functions of selected targets, guided by the similarity of binding 
site interactions. Finally, a combined approach of both compound similarity and target 
similarity was conceived and tested on the rhodopsin-like GPCR family, which was of 
great importance due to its high number of drug targets as well as association with 
diverse cognitive and sensing functions. These works demonstrated the feasibility of 
similarity-guided chemogenomic approaches as well as potential application on 
systems other than those studied here. 
 
Similarity of compounds guided the organization of compounds of different 
functional categories into hierarchical structure, presented in form of a publicly 
accessible database CFam Chemical Family database, available at 
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http://bidd2.cse.nus.edu.sg/cfam . Compounds from functional categories of approved 
drugs, clinical trial drugs, investigative drugs, bioactive molecules, human metabolites, 
natural products and patented agents partitioned the hierarchy thus provided a useful 
too facilitating chemical space analysis and virtual screening. By searching the 
database by compound name, family name, functional category or structural similarity, 
relevant compounds with information can be accessed, providing useful clues of the 
potential functions and biological targets of the compound of interest, since compounds 
with similar or same target or function tend to cluster together. Hierarchical clustering 
method guided by selected seed compounds successfully organized 490,279 
compounds in hierarchical units family, superfamily and class, demonstrating the 
capability and scalability of this method, thus providing useful concept for handling 
millions of compounds in the known chemical space. 
 
As observed from the chemical family database above, compounds with structure 
similarity clustered together and members in such clusters often share the same or 
similar targets. Previous findings also suggest similar binding site features for different 
compound against the same target. Such conserved features make the optimization of 
target-specific scoring function possible. In this thesis, the target-specific scoring 
approach was applied on three different targets trained with support vector machine 
based on simple energy terms and pharmacophore points, and obtaining satisfactory 
performance for predicting binding affinity for ligands without co-crystal structures 
with the target. This result suggested the potential application of this target-specific 




  The results from compound clustering by similarity and scoring function optimized 
for highly similar 3D structures of the same target both proved the value of similarity 
guided analysis. The two-dimensional sequence binding site sequence similarity and 
ligand set similarity guided characterization of rhodopsin-like GPCR family with 
ligands has furthered this methodology by integration of similarity of both the ligand 
and target aspects. From the two-dimensional interaction plots, regions of potential 
interest of chemogenomic approaches such as polypharmacology, scaffold hopping and 
target hopping, were explored and analyzed. Based on the observations, a potential 
multi-targeting structure was validated by experiment. These findings proved the 
success of this two-dimensional pharmacological profiling by combined ligand-based 
and sequence-based characterization approach and augmented the methodology of 
chemogenomic analysis. 
 
Finally, a tool for characterization of drugs including approved drugs, drugs in 
clinical trial and investigative drugs by their disease indications was developed. 
Further analysis on mapping between drugs and their disease indications based on 
structure similarity of drugs and classification of their disease indications may lead to 
novel characterization aspect complementing structure similarity, target interaction 
and target sequence similarity based characterization of biologically and 
therapeutically relevant compounds. 
 
  Overall, computational methods for characterization of biologically and 
therapeutically relevant compounds using similarity information were implemented, 
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evaluated and compared against previously published methods or experimental data, 
and these achievements extended the methodology of similarity-based virtual 
screening. Guided by the principle of similarity, a comprehensive seed-directed 
iterative hierarchical clustering method was developed and used to organize 
compounds with biological functions into families based on structural similarity. The 
results of this similarity based characterization were deposited into a publicly 
accessible database to facilitate virtual screening. Apart from structural similarity, a 
novel target-specific scoring algorithm combined with machine learning methods was 
developed to improve the characterization of target-binding compounds from target 
structures. Finally, a two-dimensional characterization method combining compound 
structural similarity and target sequence similarity was created and applied on G 
protein-coupled receptors. Observation and prediction on chemogenomic approaches 
for ligand discovery were obtained and validated by experiments. 
 
7.2 Limitations and suggestions for future works 
 
One major theoretical limitation throughout this work lies in the exceptions of the 
similar property principle. The relationship between structure and activity can be 
more complicated than expected. For example, in activity studies, it is possible that a 
slight change in compound structure leads to dramatic change in activity, which is 
known as the “activity cliff” [297, 298]. It partially accounted for the observations in 
characterization of compound by structural similarity, where compounds aggregated 
by structural similarity into a single family may have different activity profiles, or 
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even not share any same target. With regard to characterization of target-binding 
compounds from their targets, compounds with similar structure but significant 
difference in activities can affect the model performance as they provide similar input 
features but expect different target values. This problem also exists with the 
two-dimensional characterization approach, as the current approach discussed in this 
thesis only imposes an activity cutoff and derives patterns of all compounds within 
the cutoff, rather than distinguishes between compounds with quite different activities. 
To overcome this issue, systematic effort is required to investigate and identify the 
existence of “activity cliff” within the compounds of interest [299], and integrate such 
information into the process of applying similarity-based methods. It will also 
improve and extend the two-dimensional analysis approach by integration of activity 
information, and discuss the chemogenomic patterns on the activity landscape. 
 
  A second concern is that the mechanisms of activities were not taken into 
consideration throughout this thesis. Mechanisms of activities reveal more about the 
interaction than just a value indicating the activity strength. A compound can be an 
agonist, antagonist or agonist-antagonist to a target depending on its effect; and a 
compound can bind through the active site or act as an allosteric regulator depending 
on the site of interaction. Inclusion of such information would provide useful insight 
in interpretation of results, as well as a basis for subcategorizing compounds for 
separate modeling within each subcategory, especially for characterization of 




  The following paragraphs will address practical concerns of this thesis. 
 
Meaningful results from analysis of data depend heavily on the data quality. One 
critical data component of the work in this thesis is activity records of compounds 
against biological targets. The types of assays, forms of activities reported and 
platforms the assays conducted on all affect the accuracy and usefulness of the activity 
data. In the process of construction of compound hierarchy for the CFam database, 
activity values of compounds determine whether they fit in certain functional category. 
For optimization of target-specific scoring functions, the accuracy of activity values are 
critical to the predictive power of the SVR model. In two-dimensional pharmacology 
profiling analysis, the activity type (e.g. binder or aggregator) affects the accuracy of 
the interaction plots that fake links can be introduced between compounds and targets if 
the activity type is not carefully distinguished. The activity data source such as 
ChEMBL and PubChem report activity in different units from assays of different 
purpose, and usually it is not indicated whether a compound is an agonist or antagonist 
to a certain target. Also in order to train the scoring function to predict activities, 
activity records of different assay type were mixed and used together with implied 
approximation. Furthermore, some activity records from the data source were obtained 
in various approaches other than backed by publications, and such records were 
excluded to ensure high quality of the activity data. This partly accounts for the possible 
improvement, as extra effort can be devoted in mining other publicly available activity 





  For analysis of activity data such as clustering, model fitting and target sequence 
based characterization, the methods used in this thesis are usually not the only choice. 
For clustering of compounds, scaffold-based methods and fingerprint-based methods 
are both widely used, but due to limited computational power, only fingerprint-based 
similarity measurement was implemented. Future work can incorporate the 
scaffold-based clustering approach, complementing the current implemented approach. 
Similarly, since different choices exist for phylogenetic reconstruction of targets, it is 
worth exploring various methods to find common patterns independent of the method 
of choice. 
 
For the CFam chemical family database, since compounds are organized 
hierarchically by functional categories, continuous update efforts are needed as the 
functional category of a compound can change. For example, biologically active 
compounds can be selected for druggability investigation, and approved drugs can 
possibly be terminated or repurposed. Also, as novel compounds are being designed, 
synthesized and tested, there will be a constant need to incorporate the expansion of 
known chemical space. 
 
 
7.3 Contributions to facilitate drug repositioning 
 
Drug repositioning is the application of existing drugs to new indications [300]. The 
major advantage of drug repurposing is that known drugs have passed various safety 
tests and their toxicity profile have been well studied, resulting in less risk for failure 
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due to toxicity in the development process. Thus drug repurposing significantly 
reduces developing cost and time compared with development for new drugs [301]. 
One successful example is thalidomide, which was originally developed for relief of 
pregnancy associated nausea but was then removed from the market due to its 
teratogenic effect [70]. It was later found to be active against tumor necrosis factor α 
(TNF-α) [72], leading to its reposition in treatment of multiple myeloma. Another 
example duloxetine, which was first developed for treatment of depression, was later 
used in the treatment of stress urinary incontinence due to its excitatory effect on 
urethral sphincter motor neurons [302]. 
 
In the modern targeted therapeutics paradigm for drug development, repositioning a 
drug for new indications involves identification of new targets, and the work in this 
thesis provided useful platforms, tools and methods in such application. 
Similarity-based compound families enable the identification of novel potential 
targets by similarity match and examination of the activity profiles of compounds 
with similar structure. Target-specific scoring functions with improved predictive 
accuracy are useful in assessing the activity strength against potential targets. In 
addition, activity patterns around the drug of interest can be clearly observed and 
investigated with the two-dimensional chemogenomic characterization approach, 
which provides additional evidence and guidance for repurposing. Integration of 
methods presented in this thesis could provide promising approaches for drug 








1. Martin, Y.C., J.L. Kofron, and L.M. Traphagen, Do structurally similar molecules have similar 
biological activity? J Med Chem, 2002. 45(19): p. 4350-8. 
2. Bolton E, et al., PubChem: Integrated Platform of Small Molecules and Biological Activities. 
Chapter 12 IN Annual Reports in Computational Chemistry, 2008. 4: p. 217-240. 
3. Caron, P.R., et al., Chemogenomic approaches to drug discovery. Curr Opin Chem Biol, 2001. 
5(4): p. 464-70. 
4. Lipinski, C.A., et al., Experimental and computational approaches to estimate solubility and 
permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 
1997. 23(1–3): p. 3-25. 
5. Oprea, T.I., et al., Is there a difference between leads and drugs? A historical perspective. J 
Chem Inf Comput Sci, 2001. 41(5): p. 1308-15. 
6. Gruneberg, S., M.T. Stubbs, and G. Klebe, Successful virtual screening for novel inhibitors of 
human carbonic anhydrase: strategy and experimental confirmation. J Med Chem, 2002. 
45(17): p. 3588-602. 
7. Bocker, A., G. Schneider, and A. Teckentrup, NIPALSTREE: a new hierarchical clustering 
approach for large compound libraries and its application to virtual screening. J Chem Inf 
Model, 2006. 46(6): p. 2220-9. 
8. Willett, P., Similarity-based virtual screening using 2D fingerprints. Drug Discov Today, 2006. 
11(23-24): p. 1046-53. 
9. Riniker, S., N. Fechner, and G.A. Landrum, Heterogeneous classifier fusion for ligand-based 
virtual screening: or, how decision making by committee can be a good thing. J Chem Inf 
Model, 2013. 53(11): p. 2829-36. 
10. Lipinski, C. and A. Hopkins, Navigating chemical space for biology and medicine. Nature, 2004. 
432(7019): p. 855-61. 
11. Renner, S., et al., Bioactivity-guided mapping and navigation of chemical space. Nat Chem 
Biol, 2009. 5(8): p. 585-92. 
12. Hu, Y. and J. Bajorath, Rationalizing structure and target relationships between current drugs. 
AAPS J, 2012. 14(4): p. 764-71. 
13. Eckert, H. and J. Bajorath, Molecular similarity analysis in virtual screening: foundations, 
limitations and novel approaches. Drug Discov Today, 2007. 12(5-6): p. 225-33. 
14. Wang, Y. and J. Bajorath, Development of a compound class-directed similarity coefficient that 
accounts for molecular complexity effects in fingerprint searching. J Chem Inf Model, 2009. 
49(6): p. 1369-76. 
15. Vogt, I., et al., Exploring structure-selectivity relationships of biogenic amine GPCR 
antagonists using similarity searching and dynamic compound mapping. Mol Divers, 2008. 
12(1): p. 25-40. 
16. Biniashvili, T., E. Schreiber, and Y. Kliger, Improving classical substructure-based virtual 
screening to handle extrapolation challenges. J Chem Inf Model, 2012. 52(3): p. 678-85. 
17. Hu, G., et al., Performance evaluation of 2D fingerprint and 3D shape similarity methods in 
150 
 
virtual screening. J Chem Inf Model, 2012. 52(5): p. 1103-13. 
18. Brianso, F., et al., Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med 
Chem, 2011. 11(15): p. 1956-63. 
19. Lin, H., et al., A pharmacological organization of G protein-coupled receptors. Nat Methods, 
2013. 10(2): p. 140-6. 
20. van der Horst, E., et al., A novel chemogenomics analysis of G protein-coupled receptors 
(GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC 
Bioinformatics, 2010. 11: p. 316. 
21. C. G. Wermuth, C.R.G., P. Lindberg and L. A. Mitscher, Glossary of terms used in medicinal 
chemistry (IUPAC Recommendations 1998). Pure Appl. Chem., 1998. 70(5): p. 1129-1143. 
22. Wolber, G., et al., Molecule-pharmacophore superpositioning and pattern matching in 
computational drug design. Drug Discov Today, 2008. 13(1-2): p. 23-9. 
23. Guner, O., O. Clement, and Y. Kurogi, Pharmacophore modeling and three dimensional 
database searching for drug design using catalyst: recent advances. Curr Med Chem, 2004. 
11(22): p. 2991-3005. 
24. Dixon, S.L., et al., PHASE: a new engine for pharmacophore perception, 3D QSAR model 
development, and 3D database screening: 1. Methodology and preliminary results. J Comput 
Aided Mol Des, 2006. 20(10-11): p. 647-71. 
25. Yang, H., et al., Structure-based virtual screening for identification of novel 11beta-HSD1 
inhibitors. Eur J Med Chem, 2009. 44(3): p. 1167-71. 
26. Tanrikulu, Y., et al., Structure-based pharmacophore screening for natural-product-derived 
PPARgamma agonists. Chembiochem, 2009. 10(1): p. 75-8. 
27. Hinsberger, S., et al., Discovery of novel bacterial RNA polymerase inhibitors: 
pharmacophore-based virtual screening and hit optimization. J Med Chem, 2013. 56(21): p. 
8332-8. 
28. Valasani, K.R., et al., Acetylcholinesterase inhibitors: structure based design, synthesis, 
pharmacophore modeling, and virtual screening. J Chem Inf Model, 2013. 53(8): p. 2033-46. 
29. Jatana, N., A. Sharma, and N. Latha, Pharmacophore modeling and virtual screening studies 
to design potential COMT inhibitors as new leads. J Mol Graph Model, 2013. 39: p. 145-64. 
30. Sakkiah, S., et al., Dynamic and multi-pharmacophore modeling for designing polo-box 
domain inhibitors. PLoS One, 2014. 9(7): p. e101405. 
31. Chao, W.R., et al., Computer-aided rational drug design: a novel agent (SR13668) designed to 
mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling. J 
Med Chem, 2007. 50(15): p. 3412-5. 
32. Dayam, R., et al., Quinolone 3-carboxylic acid pharmacophore: design of second generation 
HIV-1 integrase inhibitors. J Med Chem, 2008. 51(5): p. 1136-44. 
33. Wei, D., et al., Discovery of multitarget inhibitors by combining molecular docking with 
common pharmacophore matching. J Med Chem, 2008. 51(24): p. 7882-8. 
34. Wolber, G. and T. Langer, LigandScout: 3-D pharmacophores derived from protein-bound 
ligands and their use as virtual screening filters. J Chem Inf Model, 2005. 45(1): p. 160-9. 
35. Chen, J. and L. Lai, Pocket v.2: further developments on receptor-based pharmacophore 
modeling. J Chem Inf Model, 2006. 46(6): p. 2684-91. 
36. Schuster, D., et al., Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 
inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem, 
151 
 
2008. 51(14): p. 4188-99. 
37. Brvar, M., et al., In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel 
inhibitors of DNA gyrase B. Bioorg Med Chem Lett, 2010. 20(3): p. 958-62. 
38. Cheng, T., et al., Comparative assessment of scoring functions on a diverse test set. J Chem Inf 
Model, 2009. 49(4): p. 1079-93. 
39. Jain, A.N. and A. Nicholls, Recommendations for evaluation of computational methods. J 
Comput Aided Mol Des, 2008. 22(3-4): p. 133-9. 
40. Hanley, J.A. and B.J. McNeil, The meaning and use of the area under a receiver operating 
characteristic (ROC) curve. Radiology, 1982. 143(1): p. 29-36. 
41. Sonnhammer, E.L., S.R. Eddy, and R. Durbin, Pfam: a comprehensive database of protein 
domain families based on seed alignments. Proteins, 1997. 28(3): p. 405-20. 
42. Finn, R.D., et al., Pfam: the protein families database. Nucleic Acids Res, 2014. 42(Database 
issue): p. D222-30. 
43. Sigrist, C.J., et al., New and continuing developments at PROSITE. Nucleic Acids Res, 2013. 
41(Database issue): p. D344-7. 
44. Andreeva, A., et al., Data growth and its impact on the SCOP database: new developments. 
Nucleic Acids Res, 2008. 36(Database issue): p. D419-25. 
45. Cuff, A.L., et al., Extending CATH: increasing coverage of the protein structure universe and 
linking structure with function. Nucleic Acids Res, 2011. 39(Database issue): p. D420-6. 
46. Hunter, S., et al., InterPro in 2011: new developments in the family and domain prediction 
database. Nucleic Acids Res, 2012. 40(Database issue): p. D306-12. 
47. Besnard, J., et al., Automated design of ligands to polypharmacological profiles. Nature, 2012. 
492(7428): p. 215-20. 
48. Neves, G., et al., Searching for multi-target antipsychotics: Discovery of orally active 
heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. Bioorg Med Chem, 
2010. 18(5): p. 1925-35. 
49. Schulz, S.B., et al., First and second generation antipsychotics influence hippocampal gamma 
oscillations by interactions with 5-HT3 and D3 receptors. Br J Pharmacol, 2012. 167(7): p. 
1480-91. 
50. Anighoro, A., J. Bajorath, and G. Rastelli, Polypharmacology: Challenges and Opportunities in 
Drug Discovery. J Med Chem, 2014. 
51. Peters, J.U., Polypharmacology - foe or friend? J Med Chem, 2013. 56(22): p. 8955-71. 
52. Bohm, H.J., A. Flohr, and M. Stahl, Scaffold hopping. Drug Discov Today Technol, 2004. 1(3): p. 
217-24. 
53. Lu, W., et al., Scaffold hopping approach to a new series of smoothened antagonists. Bioorg 
Med Chem Lett, 2014. 24(10): p. 2300-4. 
54. Zhao, H., Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry 
perspective. Drug Discov Today, 2007. 12(3-4): p. 149-55. 
55. Sun, H., G. Tawa, and A. Wallqvist, Classification of scaffold-hopping approaches. Drug Discov 
Today, 2012. 17(7-8): p. 310-24. 
56. Shiraishi, T., et al., Factor VIIa inhibitors: target hopping in the serine protease family using 
X-ray structure determination. Bioorg Med Chem Lett, 2008. 18(16): p. 4533-7. 
57. Tognolini, M., et al., Target hopping as a useful tool for the identification of novel EphA2 
protein-protein antagonists. ChemMedChem, 2014. 9(1): p. 67-72. 
152 
 
58. Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 
2008. 4(11): p. 682-90. 
59. Hu, Y. and J. Bajorath, Systematic identification of scaffolds representing compounds active 
against individual targets and single or multiple target families. J Chem Inf Model, 2013. 
53(2): p. 312-26. 
60. Jalencas, X. and J. Mestres, On the origins of drug polypharmacology. MedChemComm, 2013. 
4(1): p. 80-87. 
61. Tzschentke, T.M., et al., (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol 
hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake 
inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther, 2007. 323(1): p. 
265-76. 
62. Knight, Z.A., H. Lin, and K.M. Shokat, Targeting the cancer kinome through polypharmacology. 
Nat Rev Cancer, 2010. 10(2): p. 130-7. 
63. Escudier, B., et al., Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007. 
356(2): p. 125-34. 
64. Kroeze, W.K., et al., H1-histamine receptor affinity predicts short-term weight gain for typical 
and atypical antipsychotic drugs. Neuropsychopharmacology, 2003. 28(3): p. 519-26. 
65. Zhou, Z., et al., Block of HERG potassium channels by the antihistamine astemizole and its 
metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol, 1999. 10(6): 
p. 836-43. 
66. Schade, R., et al., Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med, 
2007. 356(1): p. 29-38. 
67. Roth, B.L., Drugs and valvular heart disease. N Engl J Med, 2007. 356(1): p. 6-9. 
68. Hamon, J., et al., In vitro safety pharmacology profiling: what else beyond hERG? Future Med 
Chem, 2009. 1(4): p. 645-65. 
69. Surgand, J.S., et al., A chemogenomic analysis of the transmembrane binding cavity of human 
G-protein-coupled receptors. Proteins, 2006. 62(2): p. 509-38. 
70. Hansen, J.M. and C. Harris, A novel hypothesis for thalidomide-induced limb teratogenesis: 
redox misregulation of the NF-kappaB pathway. Antioxid Redox Signal, 2004. 6(1): p. 1-14. 
71. Meierhofer, C., S. Dunzendorfer, and C.J. Wiedermann, Theoretical basis for the activity of 
thalidomide. BioDrugs, 2001. 15(10): p. 681-703. 
72. Holzgrabe, U., [An old drug as a carcinostatic. The new career of thalidomide]. Pharm Unserer 
Zeit, 2007. 36(6): p. 446-9. 
73. Mauser, H. and W. Guba, Recent developments in de novo design and scaffold hopping. Curr 
Opin Drug Discov Devel, 2008. 11(3): p. 365-74. 
74. Bemis, G.W. and M.A. Murcko, The properties of known drugs. 1. Molecular frameworks. J 
Med Chem, 1996. 39(15): p. 2887-93. 
75. Gans, K.R., et al., Anti-inflammatory and safety profile of DuP 697, a novel orally effective 
prostaglandin synthesis inhibitor. J Pharmacol Exp Ther, 1990. 254(1): p. 180-7. 
76. DeWitt, D.L., Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol, 1999. 55(4): p. 
625-31. 
77. Hall, A., et al., Discovery of a novel indole series of EP1 receptor antagonists by scaffold 
hopping. Bioorg Med Chem Lett, 2008. 18(8): p. 2684-90. 
78. Vucic, D., et al., Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: 
153 
 
implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J, 2005. 385(Pt 1): 
p. 11-20. 
79. Cohen, F., et al., Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an 
azabicyclooctane scaffold. J Med Chem, 2009. 52(6): p. 1723-30. 
80. Rush, T.S., 3rd, et al., A shape-based 3-D scaffold hopping method and its application to a 
bacterial protein-protein interaction. J Med Chem, 2005. 48(5): p. 1489-95. 
81. Hawkins, P.C., A.G. Skillman, and A. Nicholls, Comparison of shape-matching and docking as 
virtual screening tools. J Med Chem, 2007. 50(1): p. 74-82. 
82. Lauri, G. and P.A. Bartlett, CAVEAT: a program to facilitate the design of organic molecules. J 
Comput Aided Mol Des, 1994. 8(1): p. 51-66. 
83. Bocker, A., et al., A hierarchical clustering approach for large compound libraries. J Chem Inf 
Model, 2005. 45(4): p. 807-15. 
84. Engels, M.F., et al., A cluster-based strategy for assessing the overlap between large chemical 
libraries and its application to a recent acquisition. J Chem Inf Model, 2006. 46(6): p. 2651-60. 
85. Kirchmair, J., et al., Evaluation of the performance of 3D virtual screening protocols: RMSD 
comparisons, enrichment assessments, and decoy selection--what can we learn from earlier 
mistakes? J Comput Aided Mol Des, 2008. 22(3-4): p. 213-28. 
86. Warren, G.L., et al., A critical assessment of docking programs and scoring functions. J Med 
Chem, 2006. 49(20): p. 5912-31. 
87. Martin, E.J. and D.C. Sullivan, AutoShim: empirically corrected scoring functions for 
quantitative docking with a crystal structure and IC50 training data. J Chem Inf Model, 2008. 
48(4): p. 861-72. 
88. Antes, I., C. Merkwirth, and T. Lengauer, POEM: Parameter Optimization using Ensemble 
Methods: application to target specific scoring functions. J Chem Inf Model, 2005. 45(5): p. 
1291-302. 
89. Klabunde, T., Chemogenomic approaches to drug discovery: similar receptors bind similar 
ligands. Br J Pharmacol, 2007. 152(1): p. 5-7. 
90. Guba, W., et al., From astemizole to a novel hit series of small-molecule somatostatin 5 
receptor antagonists via GPCR affinity profiling. J Med Chem, 2007. 50(25): p. 6295-8. 
91. Gloriam, D.E., et al., Chemogenomic discovery of allosteric antagonists at the GPRC6A 
receptor. Chem Biol, 2011. 18(11): p. 1489-98. 
92. Schuffenhauer, A., et al., Similarity metrics for ligands reflecting the similarity of the target 
proteins. J Chem Inf Comput Sci, 2003. 43(2): p. 391-405. 
93. Raymond, J.W., C.J. Blankley, and P. Willett, Comparison of chemical clustering methods using 
graph- and fingerprint-based similarity measures. J Mol Graph Model, 2003. 21(5): p. 421-33. 
94. Hert, J., et al., Comparison of fingerprint-based methods for virtual screening using multiple 
bioactive reference structures. J Chem Inf Comput Sci, 2004. 44(3): p. 1177-85. 
95. Wilkins, C. and M. Randić, A graph theoretical approach to structure-property and 
structure-activity correlations. Theoretica chimica acta, 1980. 58(1): p. 45-68. 
96. Johnson, M.A., G.M. Maggiora, and A.C.S. Meeting, Concepts and applications of molecular 
similarity. 1990: Wiley. 
97. Willett, P., Similarity searching using 2D structural fingerprints. Methods Mol Biol, 2011. 672: 
p. 133-58. 
98. Karelson, M., Molecular descriptors in QSAR/QSPR. 2000: Wiley-Interscience. 
154 
 
99. Todeschini, R. and V. Consonni, Handbook of molecular descriptors. Vol. 11. 2000: Wiley-VCH. 
100. Li, Z.R., et al., MODEL-molecular descriptor lab: a web-based server for computing structural 
and physicochemical features of compounds. Biotechnol Bioeng, 2007. 97(2): p. 389-96. 
101. Tetko, I.V., et al., Virtual computational chemistry laboratory--design and description. J 
Comput Aided Mol Des, 2005. 19(6): p. 453-63. 
102. Todeschini, R., et al., DRAGON. 2005. 
103. Hall, L., G. Kellogg, and D. Haney, Molconn-Z. 2002. 
104. Wegner, J., JOELib/JOELib2. 2005. 
105. Yap, C.W., PaDEL-descriptor: an open source software to calculate molecular descriptors and 
fingerprints. J Comput Chem, 2011. 32(7): p. 1466-74. 
106. Steinbeck, C., et al., The Chemistry Development Kit (CDK): an open-source Java library for 
Chemo- and Bioinformatics. J Chem Inf Comput Sci, 2003. 43(2): p. 493-500. 
107. Ma, X.H., et al., Virtual screening of selective multitarget kinase inhibitors by combinatorial 
support vector machines. Mol Pharm, 2010. 7(5): p. 1545-60. 
108. Liew, C.Y., X.H. Ma, and C.W. Yap, Consensus model for identification of novel PI3K inhibitors in 
large chemical library. J Comput Aided Mol Des, 2010. 24(2): p. 131-41. 
109. Han, B., et al., Development and experimental test of support vector machines virtual 
screening method for searching Src inhibitors from large compound libraries. Chem Cent J, 
2012. 6(1): p. 139. 
110. Li, B.K., et al., In silico prediction of spleen tyrosine kinase inhibitors using machine learning 
approaches and an optimized molecular descriptor subset generated by recursive feature 
elimination method. Comput Biol Med, 2013. 43(4): p. 395-404. 
111. Carhart, R.E., D.H. Smith, and R. Venkataraghavan, Atom pairs as molecular features in 
structure-activity studies: definition and applications. Journal of Chemical Information and 
Computer Sciences, 1985. 25(2): p. 64-73. 
112. Durant, J.L., et al., Reoptimization of MDL keys for use in drug discovery. J Chem Inf Comput 
Sci, 2002. 42(6): p. 1273-80. 
113. Klekota, J. and F.P. Roth, Chemical substructures that enrich for biological activity. 
Bioinformatics, 2008. 24(21): p. 2518-25. 
114. O'Boyle, N.M., et al., Open Babel: An open chemical toolbox. J Cheminform, 2011. 3: p. 33. 
115. RDKit: Open-source cheminformatics. Available from: http://www.rdkit.org. 
116. Livingstone, D., Data Analysis for Chemists: Applications to QSAR and Chemical Product 
Design. 1995: Oxford University Press. 
117. Rogers, D.J. and T.T. Tanimoto, A Computer Program for Classifying Plants. Science, 1960. 
132(3434): p. 1115-8. 
118. Jaccard, P., Lois de distribution florale dans la Zone Alpine. 1902: Corbaz. 
119. Levandowsky, M. and D. Winter, Distance between Sets. Nature, 1971. 234(5323): p. 34-35. 
120. Patterson, D.E., et al., Neighborhood behavior: a useful concept for validation of "molecular 
diversity" descriptors. J Med Chem, 1996. 39(16): p. 3049-59. 
121. Hattori, M., et al., Development of a chemical structure comparison method for integrated 
analysis of chemical and genomic information in the metabolic pathways. J Am Chem Soc, 
2003. 125(39): p. 11853-65. 
122. Wetzel, S., et al., Interactive exploration of chemical space with Scaffold Hunter. Nat Chem 
Biol, 2009. 5(8): p. 581-3. 
155 
 
123. Wilkens, S.J., J. Janes, and A.I. Su, HierS: hierarchical scaffold clustering using topological 
chemical graphs. J Med Chem, 2005. 48(9): p. 3182-93. 
124. Molinspiration. 2014; Available from: www.molinspiration.com. 
125. Schuffenhauer, A., et al., The scaffold tree--visualization of the scaffold universe by 
hierarchical scaffold classification. J Chem Inf Model, 2007. 47(1): p. 47-58. 
126. Schwarz, R. and M. Dayhoff, Matrices for detecting distant relationships, in Atlas of protein 
sequences, M. Dayhoff, Editor. 1979, National Biomedical Research Foundation. p. 353-358. 
127. Henikoff, S. and J.G. Henikoff, Amino acid substitution matrices from protein blocks. Proc Natl 
Acad Sci U S A, 1992. 89(22): p. 10915-9. 
128. Needleman, S.B. and C.D. Wunsch, A general method applicable to the search for similarities 
in the amino acid sequence of two proteins. J Mol Biol, 1970. 48(3): p. 443-53. 
129. Smith, T.F. and M.S. Waterman, Identification of common molecular subsequences. J Mol Biol, 
1981. 147(1): p. 195-7. 
130. Altschul, S.F., et al., Basic local alignment search tool. J Mol Biol, 1990. 215(3): p. 403-10. 
131. Wang, L. and T. Jiang, On the complexity of multiple sequence alignment. J Comput Biol, 1994. 
1(4): p. 337-48. 
132. Thompson, J.D., D.G. Higgins, and T.J. Gibson, CLUSTAL W: improving the sensitivity of 
progressive multiple sequence alignment through sequence weighting, position-specific gap 
penalties and weight matrix choice. Nucleic Acids Res, 1994. 22(22): p. 4673-80. 
133. Notredame, C., D.G. Higgins, and J. Heringa, T-Coffee: A novel method for fast and accurate 
multiple sequence alignment. J Mol Biol, 2000. 302(1): p. 205-17. 
134. Sze, S.H., Y. Lu, and Q. Yang, A polynomial time solvable formulation of multiple sequence 
alignment. J Comput Biol, 2006. 13(2): p. 309-19. 
135. Sievers, F., et al., Fast, scalable generation of high-quality protein multiple sequence 
alignments using Clustal Omega. Mol Syst Biol, 2011. 7: p. 539. 
136. Jones, D.T., W.R. Taylor, and J.M. Thornton, The rapid generation of mutation data matrices 
from protein sequences. Comput Appl Biosci, 1992. 8(3): p. 275-82. 
137. Nei, M. and S. Kumar, Molecular Evolution and Phylogenetics. 2000, New York: Oxford 
University Press. 
138. Saitou, N. and M. Nei, The neighbor-joining method: a new method for reconstructing 
phylogenetic trees. Mol Biol Evol, 1987. 4(4): p. 406-25. 
139. Gascuel, O. and M. Steel, Neighbor-joining revealed. Mol Biol Evol, 2006. 23(11): p. 
1997-2000. 
140. Sokal, R.R. and C.D. Michener, A statistical method for evaluating systematic relationships. 
University of Kansas Scientific Bulletin, 1958. 28: p. 1409-1438. 
141. Felsenstein, J., Maximum Likelihood and Minimum-Steps Methods for Estimating Evolutionary 
Trees from Data on Discrete Characters. Systematic Biology, 1973. 22(3): p. 240-249. 
142. Tamura, K., et al., MEGA5: molecular evolutionary genetics analysis using maximum likelihood, 
evolutionary distance, and maximum parsimony methods. Mol Biol Evol, 2011. 28(10): p. 
2731-9. 
143. Felsenstein, J., PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics, 1989. 5: p. 
164-166. 
144. Felsenstein, J., PHYLIP - Phylogeny Inference Package (Version 3.6), 2005, Distributed by the 
author: Department of Genome Sciences, University of Washington, Seattle. 
156 
 
145. Kelly, S. and P.K. Maini, DendroBLAST: approximate phylogenetic trees in the absence of 
multiple sequence alignments. PLoS One, 2013. 8(3): p. e58537. 
146. Gao, Q.B., et al., Prediction of protein subcellular location using a combined feature of 
sequence. FEBS Lett, 2005. 579(16): p. 3444-8. 
147. Cai, C.Z., et al., SVM-Prot: Web-based support vector machine software for functional 
classification of a protein from its primary sequence. Nucleic Acids Res, 2003. 31(13): p. 
3692-7. 
148. Feng, Z.P. and C.T. Zhang, Prediction of membrane protein types based on the hydrophobic 
index of amino acids. J Protein Chem, 2000. 19(4): p. 269-75. 
149. Horne, D.S., Prediction of protein helix content from an autocorrelation analysis of sequence 
hydrophobicities. Biopolymers, 1988. 27(3): p. 451-77. 
150. Sokal, R.R. and B.A. Thomson, Population structure inferred by local spatial autocorrelation: 
an example from an Amerindian tribal population. Am J Phys Anthropol, 2006. 129(1): p. 
121-31. 
151. Han, L.Y., et al., Prediction of RNA-binding proteins from primary sequence by a support vector 
machine approach. RNA, 2004. 10(3): p. 355-68. 
152. Dubchak, I., et al., Recognition of a protein fold in the context of the Structural Classification 
of Proteins (SCOP) classification. Proteins, 1999. 35(4): p. 401-7. 
153. Bock, J.R. and D.A. Gough, Whole-proteome interaction mining. Bioinformatics, 2003. 19(1): p. 
125-34. 
154. Bock, J.R. and D.A. Gough, Predicting protein--protein interactions from primary structure. 
Bioinformatics, 2001. 17(5): p. 455-60. 
155. Karchin, R., K. Karplus, and D. Haussler, Classifying G-protein coupled receptors with support 
vector machines. Bioinformatics, 2002. 18(1): p. 147-59. 
156. Cai, C.Z., et al., Enzyme family classification by support vector machines. Proteins, 2004. 55(1): 
p. 66-76. 
157. Lloyd, S., Least squares quantization in PCM. Information Theory, IEEE Transactions on, 1982. 
28(2): p. 129-137. 
158. Hamerly, G. and C. Elkan, Alternatives to the k-means algorithm that find better clusterings, in 
Proceedings of the eleventh international conference on Information and knowledge 
management2002, ACM: McLean, Virginia, USA. p. 600-607. 
159. Melville, J.L., E.K. Burke, and J.D. Hirst, Machine learning in virtual screening. Comb Chem 
High Throughput Screen, 2009. 12(4): p. 332-43. 
160. Rice, J.A., Mathematical statistics and data analysis. 2 ed. 1995, Belmont, CA: Duxbury Press. 
161. Cortes, C. and V. Vapnik, Support-vector networks. Machine Learning, 1995. 20(3): p. 273-297. 
162. Drucker, H., et al., Support Vector Regression Machines, in NIPS1996, MIT Press. p. 155-161. 
163. Kinnings, S.L., et al., A machine learning-based method to improve docking scoring functions 
and its application to drug repurposing. J Chem Inf Model, 2011. 51(2): p. 408-19. 
164. Chang, C.-C. and C.-J. Lin, LIBSVM: a library for support vector machines, 2001. 
165. Moguerza, J.M. and A. Munoz, Support Vector Machines with Applications. 2006: p. 322-336. 
166. Burges, C.C., A Tutorial on Support Vector Machines for Pattern Recognition. Data Mining and 
Knowledge Discovery, 1998. 2(2): p. 121-167. 
167. Han, J., M. Kamber, and J. Pei, Data Mining: Concepts and Techniques. 2011: Morgan 
Kaufmann Publishers Inc. 696. 
157 
 
168. Soman, K.P.D., S.; Ajay, V., Insight into Data Mining Theory and Practice. 2006, New Delhi: PHI. 
169. Kotsiantis, S.B., I. Zaharakis, and P. Pintelas, Supervised machine learning: A review of 
classification techniques, 2007. 
170. Wu, X., et al., Top 10 algorithms in data mining. Knowledge and Information Systems, 2008. 
14(1): p. 1-37. 
171. Bhavsar, H. and A. Ganatra, A comparative study of training algorithms for supervised 
machine learning. International Journal of Soft Computing and Engineering (IJSCE), 2012. 2(4): 
p. 2231-2307. 
172. Rumelhart, D.E., G.E. Hinton, and R.J. Williams, Learning internal representations by error 
propagation, in Parallel distributed processing: explorations in the microstructure of cognition, 
vol. 1, E.R. David, L.M. James, and C.P.R. Group, Editors. 1986, MIT Press. p. 318-362. 
173. Breiman, L., Random Forests. Machine Learning, 2001. 45(1): p. 5-32. 
174. Breiman, L., et al., Classification and regression trees. 1984: CRC press. 
175. Horning, N. Random Forests: An algorithm for image classification and generation of 
continuous fields data sets. in Proceeding of International Conference on Geoinformatics for 
Spatial Infrastructure Development in Earth and Allied Sciences. 2010. 
176. Lachance, H., et al., Charting, navigating, and populating natural product chemical space for 
drug discovery. J Med Chem, 2012. 55(13): p. 5989-6001. 
177. Le Guilloux, V., et al., Visual characterization and diversity quantification of chemical libraries: 
1. creation of delimited reference chemical subspaces. J Chem Inf Model, 2011. 51(8): p. 
1762-74. 
178. Bento, A.P., et al., The ChEMBL bioactivity database: an update. Nucleic Acids Res, 2014. 
42(Database issue): p. D1083-90. 
179. Li, W., A fast clustering algorithm for analyzing highly similar compounds of very large 
libraries. J Chem Inf Model, 2006. 46(5): p. 1919-23. 
180. Matter, H., Selecting optimally diverse compounds from structure databases: a validation 
study of two-dimensional and three-dimensional molecular descriptors. J Med Chem, 1997. 
40(8): p. 1219-29. 
181. Cramer, R.D., et al., "Lead hopping". Validation of topomer similarity as a superior predictor of 
similar biological activities. J Med Chem, 2004. 47(27): p. 6777-91. 
182. Dunkel, M., et al., SuperPred: drug classification and target prediction. Nucleic Acids Res, 
2008. 36(Web Server issue): p. W55-9. 
183. Godden, J.W., F.L. Stahura, and J. Bajorath, Anatomy of fingerprint search calculations on 
structurally diverse sets of active compounds. J Chem Inf Model, 2005. 45(6): p. 1812-9. 
184. Boehm, M., et al., Similarity searching and scaffold hopping in synthetically accessible 
combinatorial chemistry spaces. J Med Chem, 2008. 51(8): p. 2468-80. 
185. Li, W., L. Jaroszewski, and A. Godzik, Clustering of highly homologous sequences to reduce the 
size of large protein databases. Bioinformatics, 2001. 17(3): p. 282-3. 
186. Qin, C., et al., Therapeutic target database update 2014: a resource for targeted therapeutics. 
Nucleic Acids Res, 2014. 42(Database issue): p. D1118-23. 
187. Law, V., et al., DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res, 2014. 
42(Database issue): p. D1091-7. 
188. Wishart, D.S., et al., HMDB 3.0--The Human Metabolome Database in 2013. Nucleic Acids Res, 
2013. 41(Database issue): p. D801-7. 
158 
 
189. Irwin, J.J., et al., ZINC: a free tool to discover chemistry for biology. J Chem Inf Model, 2012. 
52(7): p. 1757-68. 
190. IUPAC, T.I.U.o.P.a.A.C. The IUPAC International Chemical Identifier (InChI). 2011  [cited 2014; 
Available from: http://www.iupac.org/home/publications/e-resources/inchi.html. 
191. InChI Trust. InChI FAQ: 13.6. What is the collision resistance of InChIKey? 2012; Available from: 
http://www.inchi-trust.org/fileadmin/user_upload/html/inchifaq/inchi-faq.html#13.6. 
192. Bender, A., et al., How similar are similarity searching methods? A principal component 
analysis of molecular descriptor space. J Chem Inf Model, 2009. 49(1): p. 108-19. 
193. Dean, P.M., ed. Molecular Similarity in Drug Design. 1994, Chapman and Hall. 
194. Willett, P., J.M. Barnard, and G.M. Downs, Chemical Similarity Searching. Journal of Chemical 
Information and Computer Sciences, 1998. 38(6): p. 983-996. 
195. Nikolova, N. and J. Jaworska, Approaches to Measure Chemical Similarity – a Review. QSAR & 
Combinatorial Science, 2003. 22(9-10): p. 1006-1026. 
196. Bender, A. and R.C. Glen, Molecular similarity: a key technique in molecular informatics. 
Organic & Biomolecular Chemistry, 2004. 2(22): p. 3204-3218. 
197. Brown, R. and Y. Martin, The Information Content of 2D and 3D Structural Descriptors 
Relevant to Ligand-Receptor Binding. Journal of Chemical Information and Computer Sciences, 
1997. 37(1): p. 1-9. 
198. Schuffenhauer, A., V.J. Gillet, and P. Willett, Similarity searching in files of three-dimensional 
chemical structures: analysis of the BIOSTER database using two-dimensional fingerprints and 
molecular field descriptors. J Chem Inf Comput Sci, 2000. 40(2): p. 295-307. 
199. Makara, G.M., Measuring molecular similarity and diversity: total pharmacophore diversity. J 
Med Chem, 2001. 44(22): p. 3563-71. 
200. Sheridan, R.P. and S.K. Kearsley, Why do we need so many chemical similarity search methods? 
Drug Discov Today, 2002. 7(17): p. 903-11. 
201. Cruciani, G., M. Pastor, and R. Mannhold, Suitability of molecular descriptors for database 
mining. A comparative analysis. J Med Chem, 2002. 45(13): p. 2685-94. 
202. Smieja, M., et al., Asymmetric clustering index in a case study of 5-HT1A receptor ligands. 
PLoS One, 2014. 9(7): p. e102069. 
203. Xue, L., J.W. Godden, and J. Bajorath, Database searching for compounds with similar 
biological activity using short binary bit string representations of molecules. J Chem Inf 
Comput Sci, 1999. 39(5): p. 881-6. 
204. Chambers, R.J., et al., Biarylcarboxamide inhibitors of phosphodiesterase IV and tumor 
necrosis factor-α. Bioorganic & Medicinal Chemistry Letters, 1997. 7(6): p. 739-744. 
205. Thomas, G.L. and C.W. Johannes, Natural product-like synthetic libraries. Curr Opin Chem Biol, 
2011. 15(4): p. 516-22. 
206. Lopez-Vallejo, F., et al., Expanding the medicinally relevant chemical space with compound 
libraries. Drug Discov Today, 2012. 17(13-14): p. 718-26. 
207. van Hattum, H. and H. Waldmann, Biology-oriented synthesis: harnessing the power of 
evolution. J Am Chem Soc, 2014. 136(34): p. 11853-9. 
208. Huang, S.Y., S.Z. Grinter, and X. Zou, Scoring functions and their evaluation methods for 
protein-ligand docking: recent advances and future directions. Phys Chem Chem Phys, 2010. 
209. Dill, K.A., Additivity principles in biochemistry. J Biol Chem, 1997. 272(2): p. 701-4. 
210. Berman, H.M., et al., The Protein Data Bank. Nucleic Acids Res, 2000. 28(1): p. 235-42. 
159 
 
211. Huang, N., B.K. Shoichet, and J.J. Irwin, Benchmarking sets for molecular docking. J Med 
Chem, 2006. 49(23): p. 6789-801. 
212. Irwin, J.J. and B.K. Shoichet, ZINC--a free database of commercially available compounds for 
virtual screening. J Chem Inf Model, 2005. 45(1): p. 177-82. 
213. Wolpert, D.H. and W.G. Macready, No free lunch theorems for optimization. IEEE Transactions 
on Evolutionary Computation, 1997. 1(1): p. 67-82. 
214. Rafael Ö rdög and V. Grolmusz, Evaluating genetic algorithms in protein-ligand docking, in 
Proceedings of the 4th international conference on Bioinformatics research and 
applications2008, Springer-Verlag: Atlanta, GA, USA. p. 402-413. 
215. Ho, Y.C. and D.L. Pepyne, Simple Explanation of the No Free Lunch Theorem of Optimization. 
Cybernetics and Systems Analysis, 2002. 38(2): p. 292-298. 
216. Liao, J.J., Molecular recognition of protein kinase binding pockets for design of potent and 
selective kinase inhibitors. J Med Chem, 2007. 50(3): p. 409-24. 
217. Kerzmann, A., et al., BALLDock/SLICK: a new method for protein-carbohydrate docking. J 
Chem Inf Model, 2008. 48(8): p. 1616-25. 
218. Hetenyi, C., et al., Combination of a modified scoring function with two-dimensional 
descriptors for calculation of binding affinities of bulky, flexible ligands to proteins. J Am 
Chem Soc, 2006. 128(4): p. 1233-9. 
219. Breu, B., K. Silber, and H. Gohlke, Consensus adaptation of fields for molecular comparison 
(AFMoC) models incorporate ligand and receptor conformational variability into tailor-made 
scoring functions. J Chem Inf Model, 2007. 47(6): p. 2383-400. 
220. Seifert, M.H., Optimizing the signal-to-noise ratio of scoring functions for protein--ligand 
docking. J Chem Inf Model, 2008. 48(3): p. 602-12. 
221. Teramoto, R. and H. Fukunishi, Supervised scoring models with docked ligand conformations 
for structure-based virtual screening. J Chem Inf Model, 2007. 47(5): p. 1858-67. 
222. Pfeffer, P. and H. Gohlke, DrugScoreRNA--knowledge-based scoring function to predict 
RNA-ligand interactions. J Chem Inf Model, 2007. 47(5): p. 1868-76. 
223. Baroni, M., et al., A common reference framework for analyzing/comparing proteins and 
ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J Chem Inf 
Model, 2007. 47(2): p. 279-94. 
224. Radestock, S., T. Weil, and S. Renner, Homology model-based virtual screening for GPCR 
ligands using docking and target-biased scoring. J Chem Inf Model, 2008. 48(5): p. 1104-17. 
225. Kumar, A., et al., Knowledge based identification of potent antitubercular compounds using 
structure based virtual screening and structure interaction fingerprints. J Chem Inf Model, 
2009. 49(1): p. 35-42. 
226. Knox, A.J., et al., Target specific virtual screening: optimization of an estrogen receptor 
screening platform. J Med Chem, 2007. 50(22): p. 5301-10. 
227. Zhong, S., Y. Zhang, and Z. Xiu, Rescoring ligand docking poses. Curr Opin Drug Discov Devel, 
2010. 13(3): p. 326-34. 
228. Jain, T. and B. Jayaram, An all atom energy based computational protocol for predicting 
binding affinities of protein-ligand complexes. FEBS Lett, 2005. 579(29): p. 6659-66. 
229. Shaikh, S.A. and B. Jayaram, A swift all-atom energy-based computational protocol to predict 
DNA-ligand binding affinity and DeltaTm. J Med Chem, 2007. 50(9): p. 2240-4. 
230. Jain, T. and B. Jayaram, Computational protocol for predicting the binding affinities of zinc 
160 
 
containing metalloprotein-ligand complexes. Proteins, 2007. 67(4): p. 1167-78. 
231. Sotriffer, C.A., et al., SFCscore: scoring functions for affinity prediction of protein-ligand 
complexes. Proteins, 2008. 73(2): p. 395-419. 
232. Wang, R., L. Lai, and S. Wang, Further development and validation of empirical scoring 
functions for structure-based binding affinity prediction. J Comput Aided Mol Des, 2002. 16(1): 
p. 11-26. 
233. Chen, X., M. Liu, and M.K. Gilson, BindingDB: a web-accessible molecular recognition 
database. Comb Chem High Throughput Screen, 2001. 4(8): p. 719-25. 
234. Tripos International, SYBYL-X 1.2: 1699 South Hanley Rd., St. Louis, Missouri, 63144, USA. 
235. Jain, A.N., Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring 
flexibility, and knowledge-based search. J Comput Aided Mol Des, 2007. 21(5): p. 281-306. 
236. Morris, G.M., et al., AutoDock4 and AutoDockTools4: Automated docking with selective 
receptor flexibility. J Comput Chem, 2009. 30(16): p. 2785-91. 
237. Cornell, W.D., et al., A Second Generation Force Field for the Simulation of Proteins, Nucleic 
Acids, and Organic Molecules. Journal of the American Chemical Society, 1995. 117(19): p. 
5179-5197. 
238. Sanderson, R.T., Principles of electronegativity Part I. General nature. Journal of Chemical 
Education, 1988. 65(2): p. 112-null. 
239. Baird, N.C., Simulation of hydrogen bonding in biological systems: Ab initio calculations for 
 International Journal of Quantum Chemistry, 1974. 8(S1): p. 
49-54. 
240. Wesson, L. and D. Eisenberg, Atomic solvation parameters applied to molecular dynamics of 
proteins in solution. Protein Sci, 1992. 1(2): p. 227-35. 
241. Filikov, A.V., et al., Identification of ligands for RNA targets via structure-based virtual 
screening: HIV-1 TAR. J Comput Aided Mol Des, 2000. 14(6): p. 593-610. 
242. Meng, E.C. and R.A. Lewis, Determination of molecular topology and atomic hybridization 
states from heavy atom coordinates. Journal of Computational Chemistry, 1991. 12(7): p. 
891-898. 
243. Cheng, Y. and W.H. Prusoff, Relationship between the inhibition constant (K1) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. 
Biochem Pharmacol, 1973. 22(23): p. 3099-108. 
244. Lazareno, S. and N.J. Birdsall, Estimation of antagonist Kb from inhibition curves in functional 
experiments: alternatives to the Cheng-Prusoff equation. Trends Pharmacol Sci, 1993. 14(6): p. 
237-9. 
245. Craig, D.A., The Cheng-Prusoff relationship: something lost in the translation. Trends 
Pharmacol Sci, 1993. 14(3): p. 89-91. 
246. Cheng, H.C., The power issue: determination of KB or Ki from IC50. A closer look at the 
Cheng-Prusoff equation, the Schild plot and related power equations. J Pharmacol Toxicol 
Methods, 2001. 46(2): p. 61-71. 
247. Marabotti, A. and A. Facchiano, Critical assessment of side chain conformation prediction in 
modelling of single point amino acid mutation. Adv Exp Med Biol, 2010. 680: p. 283-9. 
248. Krivov, G.G., M.V. Shapovalov, and R.L. Dunbrack, Jr., Improved prediction of protein side-chain 
conformations with SCWRL4. Proteins, 2009. 77(4): p. 778-95. 
249. Xiang, Z. and B. Honig, Extending the accuracy limits of prediction for side-chain 
161 
 
conformations. J Mol Biol, 2001. 311(2): p. 421-30. 
250. Peterson, R.W., P.L. Dutton, and A.J. Wand, Improved side-chain prediction accuracy using an 
ab initio potential energy function and a very large rotamer library. Protein Sci, 2004. 13(3): p. 
735-51. 
251. Lander, E.S., et al., Initial sequencing and analysis of the human genome. Nature, 2001. 
409(6822): p. 860-921. 
252. Fredriksson, R., et al., The G-protein-coupled receptors in the human genome form five main 
families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol, 2003. 
63(6): p. 1256-72. 
253. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res, 2014. 42(Database 
issue): p. D191-8. 
254. Attwood, T.K. and J.B. Findlay, Fingerprinting G-protein-coupled receptors. Protein Eng, 1994. 
7(2): p. 195-203. 
255. Kolakowski, L.F., Jr., GCRDb: a G-protein-coupled receptor database. Receptors Channels, 
1994. 2(1): p. 1-7. 
256. Gloriam, D.E., et al., Definition of the G protein-coupled receptor transmembrane bundle 
binding pocket and calculation of receptor similarities for drug design. J Med Chem, 2009. 
52(14): p. 4429-42. 
257. Secker, A., et al., Hierarchical classification of G-protein-coupled receptors with data-driven 
selection of attributes and classifiers. Int J Data Min Bioinform, 2010. 4(2): p. 191-210. 
258. Davies, M.N., et al., On the hierarchical classification of G protein-coupled receptors. 
Bioinformatics, 2007. 23(23): p. 3113-8. 
259. Debanne, D., et al., Brain plasticity and ion channels. J Physiol Paris, 2003. 97(4-6): p. 403-14. 
260. Nelson, G., et al., Mammalian sweet taste receptors. Cell, 2001. 106(3): p. 381-90. 
261. Yona, S., et al., Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. 
FASEB J, 2008. 22(3): p. 741-51. 
262. Monk, K.R., et al., Gpr126 is essential for peripheral nerve development and myelination in 
mammals. Development, 2011. 138(13): p. 2673-80. 
263. Chandrashekar, J., et al., T2Rs function as bitter taste receptors. Cell, 2000. 100(6): p. 703-11. 
264. Huang, H.C. and P.S. Klein, The Frizzled family: receptors for multiple signal transduction 
pathways. Genome Biol, 2004. 5(7): p. 234. 
265. Dong, M. and L.J. Miller, Molecular pharmacology of the secretin receptor. Receptors 
Channels, 2002. 8(3-4): p. 189-200. 
266. Gaylinn, B.D., Growth hormone releasing hormone receptor. Receptors Channels, 2002. 8(3-4): 
p. 155-62. 
267. Overington, J.P., B. Al-Lazikani, and A.L. Hopkins, How many drug targets are there? Nat Rev 
Drug Discov, 2006. 5(12): p. 993-6. 
268. Klabunde, T. and G. Hessler, Drug design strategies for targeting G-protein-coupled receptors. 
Chembiochem, 2002. 3(10): p. 928-44. 
269. Joost, P. and A. Methner, Phylogenetic analysis of 277 human G-protein-coupled receptors as 
a tool for the prediction of orphan receptor ligands. Genome Biol, 2002. 3(11): p. 
RESEARCH0063. 
270. Jacoby, E., A Novel Chemogenomics Knowledge-Based Ligand Design Strategy—Application to 




271. Kratochwil, N.A., et al., An automated system for the analysis of G protein-coupled receptor 
transmembrane binding pockets: alignment, receptor-based pharmacophores, and their 
application. J Chem Inf Model, 2005. 45(5): p. 1324-36. 
272. Keiser, M.J., et al., Relating protein pharmacology by ligand chemistry. Nat Biotechnol, 2007. 
25(2): p. 197-206. 
273. Paradis, E., J. Claude, and K. Strimmer, APE: Analyses of Phylogenetics and Evolution in R 
language. Bioinformatics, 2004. 20(2): p. 289-90. 
274. Poulain, R., et al., From hit to lead. Analyzing structure-profile relationships. J Med Chem, 
2001. 44(21): p. 3391-401. 
275. Bureau, R., et al., Molecular design based on 3D-pharmacophore. Application to 5-HT4 
receptor. J Chem Inf Comput Sci, 2002. 42(4): p. 962-7. 
276. Bostrom, J., K. Gundertofte, and T. Liljeforsa, A pharmacophore model for dopamine D4 
receptor antagonists. J Comput Aided Mol Des, 2000. 14(8): p. 769-86. 
277. Yakar, R. and E.D. Akten, Discovery of high affinity ligands for beta-adrenergic receptor 
through pharmacophore-based high-throughput virtual screening and docking. J Mol Graph 
Model, 2014. 53C: p. 148-160. 
278. Prathipati, P. and A.K. Saxena, Characterization of beta3-adrenergic receptor: determination 
of pharmacophore and 3D QSAR model for beta3 adrenergic receptor agonism. J Comput 
Aided Mol Des, 2005. 19(2): p. 93-110. 
279. Shenderovich, M.D., et al., A three-dimensional model of the delta-opioid pharmacophore: 
comparative molecular modeling of peptide and nonpeptide ligands. Biopolymers, 2000. 
53(7): p. 565-80. 
280. Bhattacharjee, A.K., et al., Discovery of subtype selective muscarinic receptor antagonists as 
alternatives to atropine using in silico pharmacophore modeling and virtual screening 
methods. Bioorg Med Chem, 2013. 21(9): p. 2651-62. 
281. Kawamoto, H., et al., Discovery of the first potent and selective small molecule opioid 
receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- 
hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397). J Med 
Chem, 1999. 42(25): p. 5061-3. 
282. Ohta, A. and M. Sitkovsky, Role of G-protein-coupled adenosine receptors in downregulation 
of inflammation and protection from tissue damage. Nature, 2001. 414(6866): p. 916-20. 
283. Shen, H.C., et al., Discovery of biaryl anthranilides as full agonists for the high affinity niacin 
receptor. J Med Chem, 2007. 50(25): p. 6303-6. 
284. Scheiff, A.B., et al., 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and 
selective adenosine A1 receptor antagonists. Bioorg Med Chem, 2010. 18(6): p. 2195-203. 
285. Malo, M., et al., Selective pharmacophore models of dopamine D(1) and D(2) full agonists 
based on extended pharmacophore features. ChemMedChem, 2010. 5(2): p. 232-46. 
286. Horvath, D., Pharmacophore-based virtual screening. Methods Mol Biol, 2011. 672: p. 
261-98. 
287. Strategies for 3D pharmacophore-based virtual screening. Drug Discov Today Technol, 2010. 
7(4): p. e203-70. 




289. Chan, I.S. and G.S. Ginsburg, Personalized medicine: progress and promise. Annu Rev 
Genomics Hum Genet, 2011. 12: p. 217-44. 
290. Aronson, J.K., Biomarkers and surrogate endpoints. Br J Clin Pharmacol, 2005. 59(5): p. 491-4. 
291. Ludwig, J.A. and J.N. Weinstein, Biomarkers in cancer staging, prognosis and treatment 
selection. Nat Rev Cancer, 2005. 5(11): p. 845-56. 
292. Wood, P.H., Applications of the International Classification of Diseases. World Health Stat Q, 
1990. 43(4): p. 263-8. 
293. Benson, D.A., et al., GenBank. Nucleic Acids Res, 2005. 33(Database issue): p. D34-8. 
294. Kapushesky, M., et al., Gene expression atlas at the European bioinformatics institute. Nucleic 
Acids Res, 2010. 38(Database issue): p. D690-8. 
295. Prat, A. and C.M. Perou, Deconstructing the molecular portraits of breast cancer. Mol Oncol, 
2011. 5(1): p. 5-23. 
296. Cancer Genome Atlas, N., Comprehensive molecular portraits of human breast tumours. 
Nature, 2012. 490(7418): p. 61-70. 
297. Stumpfe, D., et al., Recent progress in understanding activity cliffs and their utility in 
medicinal chemistry. J Med Chem, 2014. 57(1): p. 18-28. 
298. Dimova, D., et al., Do medicinal chemists learn from activity cliffs? A systematic evaluation of 
cliff progression in evolving compound data sets. J Med Chem, 2013. 56(8): p. 3339-45. 
299. Hu, Y., D. Stumpfe, and J. Bajorath, Advancing the activity cliff concept [v1; ref status: 
indexed]. Vol. 2. 2013. 
300. Ashburn, T.T. and K.B. Thor, Drug repositioning: identifying and developing new uses for 
existing drugs. Nat Rev Drug Discov, 2004. 3(8): p. 673-83. 
301. DiMasi, J.A., et al., Cost of innovation in the pharmaceutical industry. J Health Econ, 1991. 
10(2): p. 107-42. 
302. Voelker, R., International group seeks to dispel incontinence "taboo". JAMA, 1998. 280(11): p. 
951-3. 
 
 
